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STRUCTURE, FUNCTION AND POTENTIAL APPLICANTION STUDIES OF SELENIUM
SUBSTITUTED NUCLEIC ACIDS

by

ZIYUAN FANG

Under the Direction of Zhen Huang, PhD

ABSTRACT
Nucleic Acids are the most important macromolecules in living systems. They directly
participate in storing, transferring and expressing the genetic information, thereby controlling and
regulating the function of living systems. Therefore, nucleic acid research will give us molecular
insights into lives. Meanwhile, many novel research methods based on nucleic acids have been
developed. Moreover, nucleic acid-based therapeutics have been developed rapidly over the past
several years, leading to a revolution on drug discovery and disease study at the molecular level
and the genetic level. Consequently, the structure and function studies on nucleic acids and proteinnucleic acid complexes have attracted tremendous research attention, especially in medical science
and biological chemistry.

Since oxygen and selenium are in the same main group in the periodic table, we anticipate
oxygen atoms on nucleic acids can be replaced by selenium atoms without significant perturbations
on structure and function. Previously, we successfully completed the chemical and enzymatic
synthesis of Se-modified nucleic acids (SeNA) with selenium substitutions at various positions.
Indeed, we have demonstrated that the Se-modifications would not lead to significant changes in
the structure. In addition, SeNA can largely facilitate nucleic acid-protein X-ray crystallography,
and its unique properties may lead to many other potential applications, such as gene silencing,
therapeutics and cellular imaging. This dissertation has explored potential applications of SeNA,
including therapeutic and biochemical research, via structural and functional studies. We
demonstrated that SeNA has great potential for antisense drug discovery because of its stronger
nuclease resistance, better compatibility with RNase H and more efficient gene silencing in cells.
SeNA could also be applied in cellular imaging via micro-X-ray fluorescence (microXRF), which
allowed us to establish a novel approach to image mRNA transportation in cells. With this
approach, we have successfully monitored the GFP mRNA in HeLa cell. Furthermore, we found
that SeNA doesn’t perturb the structure of DNA/DNA polymerase complex, which allows an
accurate structural determination of protein-nucleic acid complexes and provides a bright future
on X-ray crystallography of nucleic acids and their protein complexes.

INDEX WORDS: Nucleic acid, Selenium, X-ray crystallography, Gene silencing, Biosensor.
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1
1.1

GENERAL INTRODUCTION

Nucleic Acids for Biofunction Studies and Drug Discovery
Nucleic acids are the storage and carrier of genetic information and directly participate in

gene replication, transcription, and expression1-2. The control of nucleic acids can lead to the
regulation of genetic information flow and gene expression. In addition, many non-coding RNAs,
like microRNA and ribosomal RNA, participate in signal transduction directly by regulatory
functions3-4. Moreover, nucleic acid-based therapeutic strategies are effective tools in drug
discovery and disease study at the molecular level as well as the genetic level 5-6. In these
therapeutic strategies, the gene, instead of a protein product, is recognized as drug targets and the
modified oligonucleotides (including DNAs and RNAs) are applied as drug candidates. Therefore,
nucleic acids related research is essential for better understanding of diseases and identifying novel
drug candidate and target for the development of therapeutics with high efficiency to treat some
world-wide diseases. Because of the advantages of low toxicity, notable efficacy, and high
specificity, numerous nucleic acid-based potential therapeutics are under development or in
clinical trials, including nucleoside analog, antisense oligonucleotides, siRNAs, miRNAs,
aptamers and ribozymes and DNazymes7-8. Instead of the traditional attacking of aberrant proteins,
modulating expression of specific diseases’ gene by these nucleic acids therapies can lead to better
treatment. Research activities in this area require further development of new nucleic acid analogs
with improved properties.
On the other hand, the unique structures of DNA and RNA provide nucleic acids multiple
functions and properties. The negative charges on phosphate groups make nucleic acids soluble in
water, and the hydrophobic nucleobases in the center can form Watson-Crick hydrogen bonds.
Additionally, the complicated RNA secondary and tertiary structures generate enzyme-like
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catalytic functions. Recently, X-ray crystallography has been the most powerful technical tool to
provide researchers detailed 3-D structural information of nucleic acids at the atomic level, which
is helpful for us to discover new drug candidate and understand nucleic acids related biological
processes mechanisms, such as DNA replication, ribozyme catalysis, DNA transcription, and RNA
translation9-10. Despite the bottle-necks of nucleic acid crystallography and phase problem, it is
greatly promising for researchers to rely on it for nucleic acid function study and gene therapy
development11-12.

1.2

Selenium Substituted Nucleic Acids for Structural Determination
In the past half century, X-ray crystallographic technologies have largely facilitated the

structure determination of biological macromolecules, including nucleic acids and protein-nucleic
acid complexes. More and more structures of nucleic acids and nucleic acid-protein complexes
have been determined. At the same time, there are many potential nucleic acid-based therapeutics
in development, and some of them have already been approved by FDA13. These investigations
make structural and functional studies of nucleic acid-protein complexes an increasingly active
research field, thereby demanding new methodologies especially novel strategies for nucleic acid
X-ray crystallography, such as the selenium-atom-specific replacement of oxygen atoms in nucleic
acids14.
However, compared with protein crystallography, the process of structure determination of
nucleic acids and nucleic acid/protein complexes is much slower. Figure 1.1 indicates the number
of total released structures in protein data bank (PDB) since 2001. It is obvious that the increase
of nucleic acids related structures determination is much slower than the structure of protein only.
The reason is that there are some unique challenges for nucleic acid X-ray crystallography. The
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first challenge is to obtain the crystals of nucleic acids. Proteins have a variety of structural and
chemical functionalities on its surface to enable molecular interaction and could easily pack to
crystals. However, the surface of nucleic acid has a lot of negative charges and repetitive phosphate
functionalities. And there are also many nucleobases which are much alike with each other with
aromatic rings. Compared with protein, these intrinsic charges, as well as its structural dynamics,
make the crystal packing of DNA and RNA molecules much more difficult14. The crystallization
condition and buffer screening process are labor intensive, and the formation of high-quality
crystals could be hard and time-consuming. These issues have significantly slowed down the
structure determination of nucleic acids and protein-nucleic acid complexes.

140000
Protein

Nucleic Acid

Protein/NA complex

120000

100000

80000

60000

40000

20000

0
2001

2006

2011

Figure 1.1 Total released structures in PDB each year since 2001

2016
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Besides the difficulties of crystal growth, phase problem (phasing or phase determination)
is another challenge need to be overcome. During the diffraction data analysis, the application of
a Fourier transformation is required to construct the electron density map of the biological
macromolecule investigated. In the Fourier transformation, both structure factors amplitude F and
phase of the reflection α are needed to calculate the electron density. The former can be measured
during the X-ray diffraction experiment. However, the phase information is missing which is
critical to producing the correct crystal structure. Several different strategies were applied to
address this issue, such as molecular replacement (MR), isomorphism replacement (SIR; MIR)
and anomalous dispersion techniques including single- and multi-wavelength anomalous
diffraction (SAD and MAD). With an available similar model, MR should be the most convenient
and fastest method which don’t need to obtain a heavy-atom derivative. However, for novel
structures, especially for nucleic acids containing highly repetitive and stacked units15, molecular
replacement could be very difficult. A suitable model can hardly be found. So heavy-atom
derivatization method is the only way to solve the phase problem for most nucleic acid molecules.
The isomorphous replacement was successfully used in protein crystallography by soaking and
co-crystallization with heavy metal cations. However, this strategy can often cause random
hydrolysis of the phosphate backbone in nucleic acid crystallization because normally heavy metal
cations are Lewis acids. Moreover, this method requires preparing many isomorphous native
crystals and heavy atom derivatives to determine the structures. Compared with isomorphous
replacement, the SAD and MAD technique could be a better way to solve the phase problem of
nucleic acids and nucleic acid-protein complexes, which only requires one single crystal in order
to obtain all diffraction information needed for the structure determination.
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Figure 1.2 Se-atom-specific modifications on nucleic acids

To solve these problems in nucleic acid X-ray crystallography, our research group has
pioneered and developed the selenium substituted nucleic acids for structure and function studies
(Figure 1.2), establishing chemical structural biology of nucleic acids. Based on our previous
research, Se-atom-specific modifications will not cause significant structure and function
perturbations and could tailor the local structure and molecular dynamics of DNA and RNA and
to accelerate the crystallization process of these molecules. During the past several years, the
selenium atom, in the same main group of oxygen, has been introduced to many different locations
of nucleotides, including phosphate groups, sugar moiety, and nucleobases, to study its unique
structural and functional effects on nucleic acids.
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Figure 1.3 Crystal structure of RNase H complexed with the Se-modified DNA and RNA
duplex.
(A) The overall structure of Se-DNA/RNA/RNase H ternary complex determined at 1.80 Å
resolution (D132N mutant; PDB ID: 3TWH). Protein is in green; RNA and DNA strands are in
pink and orange, respectively. The red and yellow spheres are Mg2+ ions and Se atoms, respectively.
The cleavage site is indicated by the arrow.
(B) Sequences of the native and modified DNAs and RNAs. SeG and SG represent 6-Se-G and 6S-G, respectively.
(C) The Se-DNA derivatized with the 6-Se-deoxyguanosine.

We have found that selenium modification could help facilitate crystal growth significantly,
as well as rationally solving phase problem in nucleic acid X-ray crystallography, where
crystallization and phase determination are the two major challenges as we discussed before. Our
previous studies on selenium modified nucleic acid X-ray crystallography illustrate that the
selenium modification facilitates the crystal growth generally16-23, while there were no significant
structure perturbations determined24-25. It also offers a novel method for the structure determination
of the protein-nucleic acid complex, which helped to study the relationship between structure and
function of enzymes such as RNase-H (Figure 1.3)26-27. What’s more, our previous study has
revealed that the 2’-methylseleno modification can facilitate the crystallization of A-form DNA
by destabilizing the B-form helix. The reason is the large methyl selenyl group cannot tolerate a
B-helix geometry due to the steric hindrance with neighboring residues, but it fits well in the minor
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groove of the A-form helix, which helps the transformation from B-form to A-form and further
facilitates the crystallization (Figure 1.4)28.

Figure 1.4 The 2’-SeCH3 group implanted in A and B helical structures

1.3

Functional Study of Selenium Substitution on Nucleic Acids
The study of Se-derivatized nucleic acids was started since 2001 and many different kinds

of Se-modifications were introduced to DNA and RNA for structural and functional studies.
Currently, selenium can almost be introduced at any position in nucleic acids replacing the oxygen
atoms or inserting to different places on nucleotides, including sugar moiety, phosphate groups,
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and nucleobases. Some examples of each kind of modifications will be introduced to discuss the
influences and functions of selenium substitution on nucleic acids.

1.3.1 Se-modifications on sugar moiety
Among all the sites in nucleic acids for selenium derivatization, ribose 2’-position is the
most widely explored. This Se-modification could facilitate crystal growth16-19,

21-23

. Through

collaboration among Huang, Egli and other co-workers, first crystal structure of nucleic acids was
solved using direct selenium derivatization and MAD phasing (Figure 1.5A)25. After that, Micura
and co-workers have developed the 2’-Se-RNA synthesis and made it possible to synthesize a SeRNA with up to 100 nucleotides via chemical synthesis and T4 RNA ligase ligation20, 29-30. As a
successful application of 2’-Se-derivatized nucleic acid, a ligated 49 nucleotides ribozyme with 6
selenium atoms modification was crystallized, and the structure was solved in approximately 3 Å
resolution (Figure 1.5B) using MAD phasing31. This work provided new insights into the
ribozyme catalytic pocket, substrate recognition, and catalytic mechanism of stereoselective
carbon-carbon bond formation. Moreover, Ennifar and co-workers crystallized and solved some
structures of complexes of HIV-1 genomic RNA dimerization initiation site (DIS) and antibiotics
with 2’-Se-derivatization technique at 1.5 Å to 2.0 Å resolutions (Figure 1.5C)32. The great quality
of the electron density maps of these structures revealed many details of drug–RNA interactions
and offered important information for HIV-1 drug discovery.
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Figure 1.5 The DNA and RNA structures with 2'-Se-modification.
(A) 2’-Se-dU DNA octamer [5’-G(Se-dU)GTACAC-3’]2, PDB ID: 1Z7I. The red spheres
represent the selenium atoms.
(B) Structure of Diels–Alder ribozyme derivatized with the 2’-Se-functionality (PDB ID:1YLS).
The red and yellow spheres represent the selenium atoms of 2’-Se-U (red) and 2’-Se-C (yellow).
The compound in purple is the reaction product.
(C) Structure of neomycin bound to HIV-1 genomic RNA dimerization initiation site (DIS) duplex
with 2’-methylseleno derivatization. The red balls represent the selenium atoms. Neomycin
molecules are in green dots (PDB ID: 3C7R).

When compared with the native structure, both the structures of 2’-Se-DNA and 2’-SeRNA have well proven that this site-specific 2’-Se-modification does not significantly alter the
global and local structures of nucleic acids. The detailed structural and hydration studies in A-form
DNAs indicated that the selenium derivatization strategy has better structural isomorphism than
the conventional bromine derivatization. Another exciting fact is that this kind of selenium
modification at the 2’-position can significantly facilitate the crystal growth and broaden the
crystallization buffer conditions for nucleic acids16-19,

21-23

. The best explanation for this

phenomenon is that 2’-selenium modifications could lock the sugar pucker and result in better
molecular packing.
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Besides 2’-Se-modifications, other modifications, including 4’-Se-modifications33 and 5’Se-modification34, were also reported. Each of these modifications has their specific conformation
and potential applications.

1.3.2 Selenium replacement of the phosphate non-bridging oxygen
Egli and co-workers synthesized DNAs with selenium at the phosphate non-bridging
position for the crystal structure study24. DNA phosphoroselenoates (PSe-DNA) were stable for
months under the crystallization conditions. As expected, Se-modified structures are virtually
identical with native (Figure 1.6A). In addition, the Mg2+ ion coordination is all the same in the
Se-modified and native DNA structure. It is also worthy to mention that the PSe-DNA synthesized
from solid-phase synthesis was a mixture of R and S diastereomers owing to the presence of the
phosphorous chiral center. These diastereomers need to be separated by anion exchange
chromatography24. In order to obtain diastereomerically pure PSe-oligonucleotide without the
chromatography separation, our group developed enzymatic methods to synthesize the PSe-DNAs
and PSe-RNAs by the enzymatic polymerization using the diastereomerically pure nucleoside 5’(α-P-seleno)-triphosphates35-37. Klenow DNA polymerase is able to recognize both dNTPαSe
diastereomers35, while T7 RNA polymerase specifically recognizes only one NTPαSe
diastereomer out of each NTPαSe diastereomer pair36. This Se-derivatization strategy on the
backbone has been applied to solve some structures that could be extremely difficult for native
sequences. The structure of a homo-DNA [d(CGAATTCG)2] (Figure 1.6B and C)38 could be a
good example of PSe-DNAs. From this crystal structure, more detailed information about the
homo-DNA, especially the role of the backbone-base inclination and the inter-strand stacking in
pairing selectivity, was revealed.
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Figure 1.6 Structures of the phosphoroselenoate DNAs (PSe-DNA).
(A) Superimposition of the PSe-DNA (in blue; PDB: 1VRO) and the native DNA with the same
sequence [d(CGCGCG)2, in cyan; PDB: 2DCG]. The selenium atoms are shown as the yellow
spheres in the PSe-DNA.
(B) Crystal structure (PDB ID: 2H9S) of a homo-DNA [d(CGAATTCG)2]. Yellow spheres
indicate the locations of the selenium atoms in the Home-DNA used for MAD phasing.
(C) Chemical structure of the homo-DNA fragment.

1.3.3 Selenium modification on the nucleobases
Our group also led the investigation into the atom-specific modifications with selenium on
the nucleobases. The previous research provides novel insights into the base pairing and stacking
interactions of nucleic acids. Many different building block phosphoramidites of the 4-Se-T22, 6Se-dG39, 2-Se-T16 and 5-SeMe-T18 nucleosides for solid-phase synthesis and the 4-Se-T
triphosphate for enzymatic synthesis40 have been developed and synthesized successfully.
The 4-Se-T was introduced into a self-complementary octamer DNA [5’-G(2’-Se-dU)G(4Se-T)ACAC-3’, Figure 1.7A] for the structure study22. The crystal structure study indicated that
this 4-Se-T modification can shift to accommodate a larger atom, such as selenium, in order to
keep the excellent isomorphism in the overall structure with maintaining the similar base-pairing
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and duplex stability. These structural data are consistent with the UV-melting study. The seleniummediated hydrogen bond was observed in this structure with a bond length of 3.35 Å (Se∙∙∙H–N),
which is the first one demonstrated in a biological system. In addition, the 4-Se-T 5’-triphosphate
was synthesized and effectively incorporated into DNA oligonucleotides with the catalysis of
Klenow fragment of DNA polymerase I40.

Figure 1.7 Crystal structures of the Se-nucleobase-modified oligonucleotides.
(A) The 4-Se-T-modified DNA octamer [5’-G(2’-Se-dU)G(4-Se-T)-ACAC-3’]2, PDB ID: 2NSK.
(B) The 2-Se-T-modified DNA octamer [5’-G(2’-Se-dU)G(2-Se-T)ACAC-3’]2, PDB ID: 3HGD.
The red balls represent the selenium atoms on the nucleobases, and the yellow balls represent the
2’-Se atoms. The 2’-Se-functionality was incorporated in the sequences to facilitate crystallization.
(C) The 6-Se-G-DNA/RNA hybrid duplex (5’-AT(6-SeG)TC(6-SeG)-p-3’/5’-UCGACA-3’),
PDB ID: 2R7Y.

The oxygen at the 2-position of thymidine has also been successfully replaced by selenium
in our lab (Figure 1.7B)16. Besides the application in crystallography, this 2-Se-T residue has also
been tested to probe base pair specificity since the 2-position of T is involved in the T-G wobble
pair. Watson–Crick base pairs are the contributors to the sequence-dependent recognition of
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nucleic acids, genetic information storage, as well as the high fidelity of DNA polymerase
replication and RNA polymerase transcription. However, the wobble base pairing, where T (or U)
pairs with G instead of A, is commonly observed in duplexes, especially RNA duplexes, which
reduces base-pairing recognition specificity and decreases the high fidelity of enzymatic
polymerization. The T-G wobble pairing (or U-G) is caused by the shift of hydrogen bonding
between the 2-exo-oxygen on T (or U) and 1-nitrogen on G in the base pairs, while the 2-exooxygen atom is not involved in T-A (or U-A) base-pairing. The 2-position is critical for the
discrimination of T-A vs. T-G pairs (or U-A vs. U-G). Therefore, we hypothesized that the
introduction of a selenium atom at the 2-position can largely increase the electronic and steric
effects, resulting in strong discrimination between normal T-A pairing and T-G wobble pairing.
To investigate nucleic acid base-pairing fidelity and stacking through the atom-specific
mutagenesis and crystallography, we synthesized 2-Se-thymidine phosphoramidite and
incorporated it into DNAs via solid phase synthesis. The biophysical results supported our
hypothesis and indicated that the 2-Se-T-substitution largely increased the T-A base pair fidelity
by discouraging the T-G and T-C mispairs. The crystallographic study further revealed that this
selenium-atomic substitution did not significantly change the native T-A base pairing and the
overall structure. Thus, this atom-specific selenium substitution of the 2-oxygen of thymidine
provides a unique chemical strategy to enhance the base pairing specificity.
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Figure 1.8 Structure of RNase H/Se-DNA/RNA complex with 6-Se-G modification.
(A) Left: The Se-DNA/RNA-RNase H structure (PDB ID: 3TWH); Right: The native DNA/RNARNase H structure (PDB ID: 2G8U);
(B) Superimposed Native (in gray) and Se-modified (in color) complex cleavage-site interactions;
(C) Local subtle unwinding of the Se-modified duplex.

Similarly, the 6-Se-dG was incorporated into DNAs (Figure 1.7C), and the crystal
structure study of the DNA [5’-AT(6-Se-dG)TC(6-Se-dG)-p-3’] was carried out using a ternary
complex of the 6-Se-dG-DNA/RNA/RNase H27. The structure was reported with the resolution of
1.80 Å (PDB ID: 3TWH). A subtle conformation change was observed based on this highresolution structure. Comparing to the corresponding native complex with the same sequence
(PDB ID: 2G8U), RNase H recognizes the internal position, instead of binding to the junction of
the Se-modified DNA/RNA duplex. This result leads to the formation of the substrate-RNase H
complex (Figure 1.8A). This Se-modified DNA/RNA/RNase H complex was also compared with
another native RNase H complex (PDB ID: 1ZBI) which containing a longer substrate sequence.
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The Se-dG3/rC5 base pair shows a conformation change by 0.5-0.7 Å which unwinding the duplex
and slightly shift the scissile phosphate closer to the RNase H active site by approximately 0.3 Å
(Figure 1.8C). What’s more, the scissile phosphate also positions the water nucleophile in the
structure by forming a hydrogen bond (3.10 Å) (Figure 1.8B). Further RNA hydrolysis study
shows that, in the presence of Se-DNA guide, the rate of hydrolysis is about 62-fold faster, which
suggests that this subtle conformation change introduced by Se-modification significantly
accelerating the RNA cleavage.

1.4

Potential in clinical therapeutic and drug development
Compared to protein, nucleic acid attracted much less attention as drug targets in the

structure-based drug design, partially because of the lack of structural information of nucleic acids
with drug candidates. By facilitating the crystallization and improving crystal quality, Se-modified
nucleic acids can greatly promote the structure-based drug design of nucleic acids. Those detailed
3D structures can help the researcher understand the structure of drug target or even the
interactions between the targets and small molecule ligands.
Moreover, oligonucleotides itself has been studied for over 30 years as potential
therapeutics. The major oligonucleotides therapeutics containing antisense oligonucleotides,
aptamers, ribozymes, and siRNAs, were studied extensively and lots of progress has been achieved.
However, until 2017, there are only six drugs approved by FDA13. Many obstacles slow down the
development of DNA/RNA-based therapies including the vulnerability to nucleases, off-target
effects, poor delivery and low affinity. Lots of chemical modifications of nucleic acids were
developed to conquer those challenges such as phosphorothioate (PS), 2’-O-methyl (2’-OMe),
locked nucleic acids (LNAs), phosphorodiamidate morpholino oligomer (PMO) and so on41, which
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can increase affinity, nuclease resistance, delivery, and reduce off-target effects by altering the
structure and charge of the oligonucleotides.
The previous study on Se-modified nucleic acid shows that replacement of the nonbridging oxygen of DNA and RNA backbone phosphates protect the oligonucleotide from
degradation by nucleases35, 37. Thus, the Se-modified siRNA may have improved RNase resistance,
suggesting a potential therapeutic application on RNAi. Moreover, certain modifications, such as
2’-MeSe, reduce multiple conformations of nucleic acid by destabilizing other unfavorable
structure28 which can potentially increase the affinity and specificity of DNA/RNA duplex by
reducing the entropic penalty. The consequent longer half-life allowing effect delivery to tissues
of interest. Furthermore, the anticancer activity of selenium-modified nucleotides was also
reported42.
Overall, Se-derivatized nucleic acids (SeNA) possess many unique properties and show
great potential in clinical therapeutic as well as drug development. However, the studies on SeNA
are still limited and the synthesis is relatively costly, which may prevent broader applications. We
expect that further progress and applications of SeNA will be achieved in the future.
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2
2.1

SELECTIVE GENE SILENCING WITH SE-MODIFIED ANTISENSE DNA

Introduction

2.1.1 Challenges in antisense therapy
In 1978, Zamecnik and Stephenson reported that an oligonucleotide complementary to the
Rous sarcoma virus could block viral replication in chicken fibroblasts.43 This discovery opened a
new world of antisense oligonucleotides. An antisense DNA is a single-strand DNA that is 17-22
nucleotides in length and complementary to a selected gene’s mRNA and thereby specifically
inhibit expression of that gene.
There are two different strategies of antisense therapeutic, arresting and RNase H cleavage
(Figure 2.1). Modified antisense DNA could bind to target mRNA through Watson-Crick base
pairs. Formation of the RNA/DNA duplex may exert a direct steric effect, blocking the binding of
factors required for the initiation of translation or impeding translocation of the ribosome along
the mRNA resulting in chain-termination. In this way, the translation was arrested, and the target
gene could be downregulated or even silenced. Alternatively, the mRNA may be cleaved by RNase
H at the site of the RNA/DNA hybrid. RNase H is a kind of non-sequence-specific endonuclease
enzyme that catalyzes the cleavage of RNA on RNA/DNA hybrid. When mRNA was cleaved,
antisense DNA will be released and is able to bind to another mRNA and introduce the RNase H
cleavage on that mRNA as well. It is obvious that the better strategy is the one involved RNase H
because less antisense DNA is needed to have the same effect.
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Figure 2.1 Two strategies of antisense therapeutic.
(A) Arresting strategy44; (B) RNase H cleavage strategy.

In general, there are several major challenges in DNA antisense strategy: RNase H
compatibility, thermo-stability, nuclease resistance, and delivery. Due to its natural compatibility
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with RNase H, unmodified native DNA could efficiently assist the enzymatic RNA cleavage.
However, it was quickly discovered that unmodified DNA is unstable against nucleases. To
enhance the nuclease stability and duplex affinity, the enormous number of DNA chemical
modifications, mainly on the backbone and sugar, have been synthesized and applied in antisense
strategy, mainly via the mRNA-arresting mechanism. However, heavy modifications may solve
the problem of nuclease instability, but they can create some other problems like losing target and
RNase H incompatibility. The losing target problem is usually caused by a weaker ability to form
stable Watson-Crick base pairs. And the RNase H incompatibility is probably caused by disrupting
the natural dynamics of the sugar pucker and backbone and interrupting the necessary interactions.
Though gene silencing without RNase H activity can still be achieved via the mRNA-arresting
mechanism, the catalytic power of RNase H in RNA inactivation is not harnessed. This is a
significant loss in gene silencing efficiency.

2.1.2 Current modification of antisense DNA
Currently, the chemical modification is one of the effective strategies to optimize antisense
therapies. In the past decades, numerous efforts have been devoted to achieving chemically
modified nucleic acid drug molecules, which improve the nucleic acids properties tremendously
in vivo. Since the first oligonucleotide drug, Fomivirsen, got approved by FDA in 199845, there
are several oligonucleotide drugs have been approved by FDA13. And early this year 2018 in
August, Patisiran became the first FDA approved siRNA drug46. All of these oligonucleotide drugs
have one or several different kinds of modifications to stabilize them and avoid hydrolysis by
nucleases. These modifications involve all three types of internucleoside linkage or backbone
modifications, sugar modifications and nucleobase modifications41.
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Figure 2.2 Some modifications that exist in FDA approved antisense drugs.
(A) Phosphorothioate; (B) 2’-O-Alkyl; (C) LNA; (D) 5-methyl-C.

2.1.2.1 Internucleoside linkage or backbone modifications
These kind modifications are also referred to as the first generation of chemically modified
antisense agents, including phosphorothioate, methylphosphonate, N-3’-phosphoramidate and
many other modifications.
Among them, phosphorothioate oligonucleotides are the most successful in gene silencing
(Figure 2.2A). Among the FDA approved drugs, Fomivirsen, Mipomersen, and Nusinersen
involve this kind of modification. Introducing phosphorothioate linkage to oligonucleotides could
significantly increase the resistance to nuclease degradation. In addition, phosphorothioate
oligonucleotides could also permit RNase H, form regular Watson-Crick base pairs, carry negative
charges for cell delivery as compared to natural phosphodiesters47-49. However, their binding
affinity to target mRNA sequences and specificity are less satisfactory50. Despite the disadvantages,
phosphorothioate oligonucleotides are the most widely used and successful modification for
oligonucleotide drugs.
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2.1.2.2 Sugar modifications
In recent years, there are great progress in the synthesis of conformationally constrained
nucleoside analogues by modifying the sugar moiety in various ways. These modifications include
synthesis of nucleoside analogs containing an electronegative atom or substituent at the 2’-position
of sugar51-52, synthesis of bicyclic nucleoside analogs having an extra ring fused to the sugar
moiety53-58 and some other methods. 2’-O-Methyl (2’-OMe) (Figure 2.2B) is a good example for
the former while locked nucleic acid (LNA) (Figure 2.2C) is a widely used example for the latter.
These secondary generation oligonucleotides could solve some problem of poor binding affinity
to the target RNA, lack of specificity and low cellular uptake that phosphorothioate could have.
The major structural difference between DNA and RNA is RNA has a 2’-OH group on
sugar ring, which leads to C3’-endo conformation. The RNA binding affinity of antisense
oligonucleotides could be improved by mimicking RNA structures with 2’-modified nucleosides.
Electronegative substituents like fluorine and oxygen influence the furanose sugar C3’-endo
conformation59 and make it easier to form A-type duplexes with target RNA strand52. Various
reported 2’-substitutions have shown excellent results in antisense therapeutics as they provide
high metabolic stability and high affinity to target the complementary mRNA, such as 2’-OMe and
LNA. Mipomersen and Nusinersen are good examples of FDA approved drugs which contain this
kind of modifications.

2.1.2.3 Nucleobase modifications
Normally most scientists modify the nucleobases to increase the binding affinity of
oligonucleotides instead of nuclease resistance because nucleobases provide the prime recognition
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site for Watson–Crick base pairs60. Thus, nucleobase modifications are less popular than those
backbone and sugar modifications. However, some kinds of modifications also have great
applications in antisense oligonucleotide drugs. The most attractive sites for substitution of the
nucleoside bases are those positions in the major grooves because modifications on these positions
neither interfere with base pairing nor induce steric hindrance and influence the general geometry
of the double helix61-63.
The stacking interactions between the planar heterocycles of nucleic acids are largely
responsible for the stability of DNA and RNA duplexes. Maximizing stacking interactions through
chemical modification provides a means of creating duplex helices of greater stability. However,
so far there are no FDA drugs with modifications in this way, despite the fact that Mipomersen
and Nusinersen have 5-methyl-C modifications (Figure 2.2D).

2.1.3 The advancement of selenium modifications for antisense drugs
As we discussed before, even though a lot of various modification methods have been
developed, none of them can solve all the problems. The basic conflict is that atom specific
modifications may not be able to confer sufficient resistance to nucleases or decrease the
specificity and binding affinity, while heavy modifications could lead to loss of RNase H
compatibility.
However, we think selenium atom specific modification could be a solution that can solve
all those problems. First of all, selenium is a kind of essential micronutrients in the human body,
so it has low toxicity. And We spent many years on Se-modified nucleic acids research and made
a lot of progress in the past 15 years. We found that selenium substitution of the non-bridging
oxygen of DNA and RNA backbone phosphates protect the oligonucleotide from degradation by
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nucleases35,

37

. On the other hand, the 2-Se-T modification could significantly increase the

specificity and binding affinity of Watson-Crick base pairs and avoid wobble pairs64-65. What’s
more, the most exciting result is that we found 6-Se-dG modified oligonucleotides could not only
maintain but even increase the RNase H activity27.
Although these modifications are at different positions, we believe Se-modified nucleic
acids have the potential to become a novel successful antisense oligonucleotide drug. We would
like to further study whether there is a possibility to find a single atom specific selenium substituted
modification that could solve all the problems that we mentioned before. In this way, we
synthesized 5-methylselenium-thymidine (Figure 2.3). 5-methylselenium-thymidine contains a
selenium atom at 5 position on the pyrimidine ring on thymidine. The 5 position does not involve
in base pair formation, so we predict this modification will not affect the ability forming stable
base pairs with adenosine on target mRNA. And the modification is in the major groove while
when RNase H is binding to the minor groove of DNA/RNA duplex. Therefore, we believe this
modification will not lose the compatibility with RNase H. However, we believe base
modifications can also stabilize the antisense from nucleases. To prove our hypothesis, we insert
it to oligonucleotides to investigate how it performs as antisense oligonucleotide and whether it
has therapeutic potential as an antisense drug.
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Figure 2.3 Structure of 5-methyselenium-thymidine.

2.2

Material and Methods

2.2.1 Se-modified antisense DNA resistance to serum
Kinase reaction for DNA substrate: Set up 20 μL reaction with DNA substrate (2 μL, 50
μM), T4 polynucleotide kinase (1 μL, Biolab), [γ-32P]-ATP (1 μL, PerkinElmer) and 10× kinase
reaction buffer (2 μL, Biolab) at 37 °C for 1 h. Stop the reaction by adding high concentration
NaCl (1 μL, 3M). Add ethanol (11 μL) and keep at -20 °C for 15 min. Centrifuging at 14,800 rpm
for 20 min. Remove the supernatant carefully. Let it dry and redissolve the labeled DNA in water
(10 μL).
Digestion of labeled DNA substrate by Serum: Set up 5 μL reaction with labeled DNA
substrate (1 μL, 5 μM), and Fetal Bovine Serum (final 4% v/v, Thermofisher) at 37 °C. Stop the
reaction by adding dye (10 μL).
Polyacrylamide gel electrophoresis (PAGE) detection: Prepare 19% polyacryl-amide
gel (16.8 g urea dissolve in 20 mL 40% acrylamide and 8 mL 5× TBE buffer, add 100 μL 10%
APS and 20 μL TEMED). Load samples and start electrophoresis in 1× TBE buffer (21.6 g Tris
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base, 11 g Boric Acid, 1.5 g EDTA add water to 2 L and adjust pH to 8.3) at 800 V for 1 h. Place
the gel on dryer for 2 h. Expose on film for 1 h and develop. Gel image was quantified by
ImageQuant TL software.

2.2.2 RNase H activity with Se-modified antisense DNA
2.2.2.1 RNase H expression and purification
Transformation of RNase H plasmid to BL21: Place human RNase H plasmids (From
Dr. Wei Yang’s lab) and competent BL21 cell on ice bath. Add plasmid (1 μL, 200 ng/μL) to the
competent cell and keep on ice bath for 30 min. Keep it at 42 °C water bath for 90 s. Then put it
back on ice bath for 3 min. Add S.O.C medium (200 μL, Invitrogen) and shake at 37 °C 225 rpm
for 45 min. Then pour 100 μL culture to the LB plate with 100 μg/mL ampicillin. Incubate at 37 °C
overnight.
Expression of RNase H: Pick single colony from the LB plate into 30 mL autoclaved LB
broth with 100 μg/mL ampicillin. Shake at 37 °C 225 rpm overnight. Then add 10 mL overnight
incubated BL21 to each litter of 2×1 L LB broth with 100 μg/mL ampicillin and shake at 37 °C
225 rpm for 3 h. Add IPTG (1 mL, 1 mol /L) to each litter of the broth to induce the expression of
RNase H and continue shaking overnight at 20 °C. Harvest the cell by centrifuging at 4 °C 5,000
rpm for 30 min. Keep the precipitation at -80 °C. Dissolve the cell in His-tag column buffer A (20
mM Tris pH 7.4, 1 M NaCl, 10 mM Imidazole, 5% Glycerol). Sonicate the cells with 60 × 15 s
bursts. After each 15 s sonication wait 20 s to let the suspension cool down. Centrifuge at 4 °C
10,000 rpm for 30 min. Keep the supernatant at -80 °C.
Purification by His-tag column: Wash the column by buffer B (20 mM Tris-HCl pH 7.4,
1 M NaCl, 300 mM Imidazole, 5% Glycerol) and followed by buffer A each for 5-column-volume.
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Load sample. Wash the column by buffer A until the UV value is flat. Then wash the column by
10% buffer B until the UV value almost go back to the low value. Elute sample by gradient from
buffer A to buffer B (up to 100% in 60 min). Dialyze the protein against 2 L Phenyl column buffer
B (20 mM Tris-HCl pH 7.4, 100 mM NaCl, 5% Glycerol) overnight. Detect the concentration of
sample by UV analysis. Use thrombin to cleavage His-tag by the concentration of 5 U/mg. Add
same volume of buffer C [20 mM Tris-HCl pH 7.4, 100 mM NaCl, 4 M (NH4)2SO4, 5% Glycerol].
Purification by Phenyl column: Wash the Phenyl column by buffer B (20 mM Tris-HCl
pH 7.4, 100 mM NaCl, 5% Glycerol) and then buffer A [20 mM Tris-HCl pH 7.4, 100 mM NaCl,
2 M (NH4)2SO4, 5% Glycerol], each for 5-column-volume. Load sample. Wash the column by
buffer A until the UV value is flat. Elute sample by program increased buffer B (up to 100% in 60
min). Dialyze the protein against 2 L storage buffer (20 mM Tris-HCl pH 7.4, 2.8 mM βmercaptoethanol, 100 mM NaCl, 5% Glycerol) overnight. Concentrate the sample to 8 mg/mL (0.5
mmol/L) and store the enzyme at -80 °C.
SDS-PAGE: Prepare the gel-loading sample with protein sample (2 μL) in mixture of
water (6 μL) and 5×loading buffer (2 μL, 250 mM Tris-HCl pH 6.8, 10% SDS, 0.02%
bromophenol blue, 5% β-mercaptoethanol, 30% Glycerol). Load samples on 4%-20% SDS gel
(Bio-rad) and start electrophoresis in 1 × Running buffer (3.02 g Tris base, 14.4 g glycine, 1 g
SDS, add water to 1 L and adjust pH to 8.3) at 150 V for 40 min. Take out the gel and put in
Coomassie Brilliant Blue Staining Solution (Bio-Rad) in microwave for 1 min. Then put in
destaining buffer (10% ethanol and 10% acetic acid in water) and shake at 37 °C for 1 h.
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2.2.2.2 RNase H reaction
Digestion of biotin labeled RNA substrate by RNase H: Set up 10 μL reaction with
biotin labeled RNA substrate (1 μL, 1 μM), DNA template (1 μL, 1 μM), 10× RNase H reaction
buffer (1 μL, Biolab) and RNase H (1 μL, 100 nM) at 37 °C. Stop the reaction by adding dye (10
μL).

2.2.2.3 Biotin labeled RNA substrate detection
Polyacrylamide gel electrophoresis (PAGE) and transfer membrane: Prepare 19%
polyacrylamide gel (16.8 g urea dissolve in 20 mL 40% acrylamide and 8 mL 5×TBE buffer, add
100 μL 10% APS and 20 μL TEMED). Load samples and start electrophoresis in 1× TBE buffer
(21.6 g Tris base, 11 g Boric Acid, 1.5 g EDTA add water to 2 L and adjust pH to 8.3) at 150 V
for 1 h. Soak the biodyne B nylon membrane (Thermofisher), gel and filter papers in 1× TBE
buffer. Assemble the transfer sandwich and make sure no air inside. Transfer with Bio-rad TransBlot Turbo at 1.3 mA for 7 min.
Incubation and imaging: Block the membrane with warmed blocking buffer (20 mL,
Thermofisher) for 30 min. Prepare conjugate/blocking buffer solution by adding the stabilized
streptavidin-horseradish peroxidase conjugate (70 μL) to warmed blocking buffer (20 mL,
Thermofisher). Incubate the membrane in conjugate/blocking buffer for 20 min. Wash membrane
four times for 5 minutes each in 1×wash solution (20 mL) with gentle shaking. Incubate membrane
in substrate equilibration buffer (30 mL) for 5 minutes with gentle shaking. Prepare
chemiluminescent substrate working solution by adding luminol/ enhancer solution (6 mL,
Thermofisher) to stable peroxide solution (6 mL, Thermofisher). Pour the substrate working
solution onto the membrane and incubate membrane in the substrate solution for 3 minutes.
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Remove and wrap the moist membrane in plastic wrap. Place the membrane in a film cassette and
expose to film. Develop the film. Gel image was quantified by ImageQuant TL software.

2.2.2.4 UV-thermal denaturation
UV-thermal denaturation: The thermal denaturation experiments were performed on a
Varian CARY-300 spectrophotometer equipped with a Peltier thermoprogrammer for data
collection and analysis. Stoppered quartz cuvettes of 10 mm optical path length and 1 ml volume
were used for the measurements. The cell holder was thermostatted with circulating water. The
DNA/RNA samples were prepared by diluting to 4 μM each strand in buffer (350 mM NaCl, 10
mM sodium phosphate pH 7.0, 0.1 mM EDTA) and then annealing by heating up to 90 °C for 2
min and then slowly cool down to 4 °C. The temperature dependence of the absorption value of
the DNA was monitored at 260 nm. The temperature of the cell holder was increased from 4 °C to
60 °C at a rate of 0.5 °C/min. A temperature probe, immersed directly in a control cuvette,
measured the sample temperature. The thermal melting temperature (Tm) was determined from the
peak of the computer-generated first derivative of the absorbance versus temperature profile.

2.2.3 Structure study on DNA/RNA/RNase H complex
Crystallization of DNA/RNA/RNase H complex: Prior to co-crystallization with RNase
H, the purified native or Se-modified DNA (5'-ATGTCG-3') and RNA (5'-UCGACA-3') were
annealed at 1:1 molar ratio by first heating the mixture to 90 °C for 1 min, and then allowing it to
cool slowly down to 25 °C. The resulting DNA/RNA duplex was mixed with the protein (final
concentration: 2 mg/mL) at 1:1 molar ratio in the presence of 2 mM MgCl2. Co-crystallization of
Se-DNA/RNA hybrid with RNase H was achieved by screening with the QIAGEN Classics Suite
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Kit (www.qiagen.com). By using the sitting-drop vapor diffusion method at 25 °C, the crystals
were readily obtained from the mixture #96 of the crystallization screen [Buffer: 0.1 M MES, pH
6.5; precipitant: 12% (w/v), PEG 20000].
Data collection and structure determination: Crystal diffraction data of the SeDNA/RNA/RNase H complex were collected at beamline 8.2.1 and 8.2.2 in the Advanced Light
Source (ALS). 25% glycerol was used as cryoprotectant while X-ray data were collected under the
liquid nitrogen stream at 100 °K. Crystal of Se-DNA/RNA/RNase H complex diffracted X-rays to
1.80. The data were processed and scaled using HKL2000, and the structures were solved by
molecular replacement using Phasing in CCP4i with Dr. Wei Yang solved structure (PDB# 2g8u)
as model. The resulted model was refined using Refmac5 within CCP4i. The modified DNA was
modeled into the structure using Coot. Metal ions and water molecules were added either
automatically or manually using Coot.

2.2.4 Cellular level gene silencing with Se-modified antisense DNA
2.2.4.1 HeLa cell culture
HeLa Cell Recovery: Take the cell out from liquid nitrogen and keep it in 37 °C water
bath. Centrifuge cells for 4 min at 1,000 rpm as soon as the media melt. Remove the supernatant.
Resuspend cells in about 1 mL media. Transfer the cells to a cell culture flask with about 10 mL
media. Continue culture the cell in incubator and change the media in 24 h.
HeLa cell passaging and splitting: Check cells in flask under microscope to confirm that
the cells are 80% - 100% confluent. Use the aspirator, empty liquid media covering cells. Use PBS
(5 mL, Thermofisher) to wash the cells for two times. Add trypsin (1 mL, Thermofisher) to flask
and keep in incubator at 37 °C for about 3 min. Check cells in flask under microscope to confirm

30

that the cells are detached. Add DMEM media (5 mL, Thermofisher) to the cells and then transfer
to a 15 mL tube. Centrifuge cells for 4 min at 1,000 rpm. Remove the supernatant. Cell pellet
should remain at base of tube. Resuspend cells in about 10 mL and separate them to 3 or 4 flasks.
Continue culture the cell in incubator.
HeLa cell cryopreservation: Check cells in flask under microscope to confirm that the
cells are 80% - 100% confluent. Use the aspirator, empty liquid media covering cells. Use PBS (5
mL, Thermofisher) to wash the cells for two times. Add trypsin (1 mL, Thermofisher) to flask and
keep in incubator at 37 °C for about 3 min. Check cells in flask under microscope to confirm that
the cells are detached. Add DMEM media (5 mL, Thermofisher) to the cells and then transfer to a
15 mL tube. Centrifuge cells for 4 min at 1,000 rpm. Remove the supernatant. Cell pellet should
remain at base of tube. Resuspend cells in about 1 mL media with DMSO (100 μL). Transfer the
cells to a 1.5 mL Eppendorf tube. Keep the cell at 4 °C for 30 min. Then move to -20 °C for 1 h.
Keep the cells at -80 °C overnight. Finally keep the cells in liquid nitrogen.

2.2.4.2 Transfection and fluorescence detection
Transfection: Check cells in flask under microscope to confirm that the cells are 70% 90% confluent. Dilute enhanced green fluorescence protein (eGFP) plasmid (0.5 μL, 1 μg/μL) and
antisense DNA (1 μL, 10 μM) in Opti-MEM medium (200 μL, Thermofisher). Dilute
Lipofectamine Reagent (1.5 μL, Thermofisher) in Opti-MEM medium (200 μL, Thermofisher).
Add diluted DNA to diluted Lipofectamine 2000 reagent and then incubate for 5 min at room
temperature. Add DNA-lipid complex to cells. Detect the cells under fluorescence microscope
after 24 h.
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Fluorescence detection with plate reader: Grow cells on 12-well-plate. Allow cell to
continue grow for 24 h or 48 h after transfection. Set excitation wavelength as 488 nm and emission
wavelength as 509 nm. Fluorescence of the cell plates was quantified by plate reader.

2.2.4.3 Western blotting
Cell Collection: Use the aspirator, empty liquid media covering cells. Use PBS (5 mL,
Thermofisher) to wash the cells for two times. Add trypsin (1 mL, Thermofisher) to flask and keep
in incubator at 37 °C for about 3 min. Check cells in flask under microscope to confirm that the
cells are detached. Add DMEM media (5 mL, Thermofisher) to the cells and then transfer to a 15
mL tube. Centrifuge cells for 4 min at 1,000 rpm. Remove the supernatant. Cell pellet should
remain at base of tube. Add Ripa Lysis buffer (200 μL, Thermofisher) and keep on ice for 30 min.
Then centrifuge the samples for 30 min at 10,000 rpm. Add 5× loading buffer (40 μL, 2 μL, 250
mM Tris-HCl pH 6.8, 10% SDS, 0.02% bromophenol blue, 5% β-mercaptoethanol, 30% Glycerol).
Boil the sample at 100 °C for 5 min.
SDS-PAGE: Load samples on 4%-20% SDS gel (Bio-rad) and start electrophoresis in 1×
Running buffer (3.02 g Tris base, 14.4 g glycine, 1 g SDS, add water to 1 L and adjust pH to 8.3)
at 150 V for 40 min.
Transferring membrane: Prepare the PVDF membrane (Bio-rad) soaking in methanol
for about 1 min. Soak the membrane, gel and papers in the transfer buffer. Assemble the transfer
sandwich and make sure there is no air inside. Transfer with Bio-rad Trans-Blot Turbo at 1.3 mA
for 7 min.
Antibody incubation and imaging: Wash the membrane with TBST (20 mM Tris-HCl
pH 7.5, 150 mM NaCl, 0.1% Tween 20). Block the membrane with 5% milk in TBST at room
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temperature for 1 h. Incubate the membrane with primary antibody overnight at 4 °C. Wash the
membrane with TBST for 3 times. Incubate the membrane with secondary antibody at temperature
for 1 h. Wash the membrane with TBST for 3 times. Then incubate the membrane with AP
substrate for 3 min. Remove and wrap the moist membrane in plastic wrap. Place the membrane
in a film cassette and expose to film. Develop the film. Gel image was quantified by ImageQuant
TL software.

2.3

Results and Discussion

2.3.1 Se-modified antisense DNA resistance to serum
Five DNAs shared the same sequence were used to test the resistance to serum. One of
them is native and other four have 5-MeSe-T modified at different positions. Their sequences and
MALDI-MS analysis information are shown in Table 2.1.

Table 2.1 MALSI-TOF MASS analysis of 5-SeMe-T containing DNA for resistance test
#
2-1
2-2
2-3
2-4
2-5

DNA Sequence
5’- GTG CAC TGA TCA ATT AAT GTC GAC-3’
5’- GTG CAC TGA TCA ATT AAT GTC GAC-3’
5’- GTG CAC TGA TCA ATT AAT GTC GAC-3’
5’- GTG CAC TGA TCA ATT AAT GTC GAC-3’
5’- GTG CAC TGA TCA ATT AAT GTC GAC-3’

Calc. [M+H+]+
7352.9
7432.8
7432.8
7432.8
7432.8

Observed
7353.1
7433.2
7439.9
7437.1
7438.3

We set up the reactions with all five DNAs in 4% serum for 20 minutes and 60 minutes to
compare their resistance to serum. The results are displayed in Figure 2.4. It is obvious that DNA
2-5 has the best resistance among all the sequences. And from the statistical result, we can also
find all modified DNA has a better resistance to serum compared with native DNA.

33

Figure 2.4 Resistance to serum of all five DNAs.
(A) Gel image of all 5 DNA resistance test to serum for 20 and 60 minutes.
(B) Statistical result of several repeats of the experiment.

We have further compared the time course digestion curve of DNA 2-1 and 2-5 (shown in
Figure 2.5). It is very interesting that native DNA 2-1 was digested immediately after mixed with
serum and continuously digested until 60 minutes later when there was almost no full-length DNA
remaining. On the other hand, DNA 2-5 was also digested when mixed with serum. However, after
about 20 minutes digestion, the full-length DNA kept about 60% remaining and no longer digested.
We think the DNases in the serum were able to bind to the Se-modified DNA, but it might have

34

difficulties to cleave the substrate and finish the reaction. That’s why the reaction rate was getting
lower and lower and the full-length DNA finally kept about 60% remaining. Another possible
explanation is that our modified antisense DNA make the RNase H enzyme lose its activity. No
matter which is the reason that made this result happened, it proved that our 5-Se-T-modified DNA
could increase the resistance against blood serum.

Figure 2.5 Time course experiment of resistance to serum of DNA 1 and 5.
(A) Gel image of time course serum resistance test for DNA 2-1 and 2-5.
(B) Digestion curve of DNA 2-1 and 2-5 during the time course experiment.
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2.3.2 RNase H activity with Se-modified antisense DNA
RNase H is a kind of sequence non-specific nuclease that can digest the RNA when
complementary DNA is hybridized, therefore, the RNase H mediated degradation of target mRNA
is one of the basic mechanisms for antisense drug working. Some of the modifications in synthetic
oligonucleotides could cause the loss of RNase H activity, probably due to the restriction in DNA
backbone dynamic. Thus, although it was proved that our nucleobase modification could
dramatically improve the stability against serum, whether it could still keep RNase H digestion on
complementary mRNA is another concern.

2.3.2.1 RNase H expression and purification
RNase H (Bacillus halodurans) truncated (TR), and truncated mutant (D132N) constructs
(pET 42 and pET13, respectively) were kindly given by Dr. Wei Yang lab at NIH as a gift. The
truncated RNase H (59-196 aa) was created and retains the RNA hydrolytic activity on RNA/DNA
duplex. Truncated inactive RNase H mutant was created, for crystal structure study, by mutating
the aspartate residue (D132) of the truncated RNase H to asparagine (D132N). This mutation
abolishes the metal ion coordination (B site) capability of the enzyme and makes the enzyme
inactive catalytically.
Protein expressions were carried out in BL21 (DE3; pLys E. coli; purchased from
Invitrogen). Then after two columns purification, we obtained pure truncated RNase H. We kept
the samples in each step of purification running PAGE gel as in Figure 2.6.
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Figure 2.6 RNase H purification.
1: Supernatant after cell lysis; 2: Purified by Ni column; 3: After thrombin digestion and buffer
change; 4: Purified by phenyl column.

2.3.2.2 Se-modified antisense DNA’s impact on RNase H cleavage
We designed hexamer DNA and RNA for RNase H digestion test. Four DNAs shared the
same sequence were used as DNA guide in RNase H cleavage. One of them is native, two have
single modification on different positions while the last one is double modified on both positions.
The sequence and MALDI-MS analysis information are in Table 2.2.

Table 2.2 MALDI-TOF MASS analysis of DNA and RNA for digestion test
#
DNA Sequence
Calc. [M+H+]+ Observed
2-6
5’- ATG TCG-3’
1808.3
1807.3
2-7
5’- ATG TCG-3’
1887.3
1886.5
2-8
5’- ATG TCG-3’
1887.3
1885.7
2-9
5’- ATG TCG-3’
1966.2
1965.2
Biotin-RNA 5’-Biotin- UCG ACA-3’
-
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We set up reactions with RNase H, DNA template and biotin-labeled RNA substrate
(purchased from Integrated DNA Technologies) and build up time course curve of RNA digestion
with different DNA templates. The results are displayed in Figure 2.7.

Figure 2.7 RNase H digestion curve of hexamer RNA binding to different DNA template.

We surprised to find all the modified DNA guides keep the compatibility with RNase H
and all of them make RNase H have even higher activity. We calculated the initial rate of the
curves and found that all the modified DNAs lead to faster initial reaction rate and double modified
DNA 2-9 has the highest value. This result indicates our Se-modified DNA has good RNase H
compatibility and even makes RNase H has higher activity.
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However, because the sequence for our DNA/RNA duplex is very short, most of them in
solution at room temperature may not appear to be duplexes. Since RNase H can only bind to
DNA/ RNA duplexes to cleavage the RNA strand, that could be a question that how the Semodification can improve the activity of RNase H. A possible explanation is that the Semodification may stabilize the duplex and increase the ratio of DNA/RNA duplexes in aqueous.
However, the previous research based on 5-Se-T modified DNA duplexes does not support this
result. It is reported that 5-Se-T modified DNA duplexes have almost the same Tm comparing with
native DNA with the same sequence66. DNA/RNA duplex may have the different performance
with DNA duplex, so we also measured the Tm for all four duplexes. The results are shown in
Table 2.3.

Table 2.3 Relative initail catalysis rate and Tm for different DNA/RNA duplexes
DNA #
2-6
2-7
2-8
2-9

DNA/RNA duplex sequences
5’- ATG TCG-3’ / 5’- UCG ACA3’
5’- ATG TCG-3’ / 5’- UCG ACA3’
5’- ATG TCG-3’ / 5’- UCG ACA3’
5’- ATG TCG-3’ / 5’- UCG ACA3’

Tm
13.5 ± 0.5 °C
13.1 ± 0.7 °C
13.2 ± 0.5 °C
13.4 ± 0.4 °C

It is obvious that Se-modifications do not make significant differences on the Tm of DNA/
RNA duplexes. So the thermos-stability of duplexes is not the critical reason of RNase H activity
increase. We need to carry out a different explanation that why Se-modification can activate RNase
H. In this way, we need to look in the structure of RNase H/DNA/RNA complex and try to draw
out a better explanation on interactions between RNase H and DNA/RNA duplexes.
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2.3.3 Structure study on RNase H/DNA/RNA complex
We already proved that our modified DNA have almost the same or sometimes even better
ability to work with RNase H and explained that the reason has nothing to do with the thermosstability. In order to understand how this happened through structural biology, we did crystal
growth and X-ray structure determination to study how selenium affects the RNase H complex.
The structure of Bacillus halodurans RNase H complexed with DNA/RNA duplex was well
determined before by Dr. Wei Yang’s lab. Here we use the same sequences of DNAs and native
RNA (5’-UCGACA-3’) for catalytic experiments (DNA sequence information is displayed in
Table 2.2).

2.3.3.1 Crystallization of RNase H/DNA/RNA complex
We mixed 0.5 mM DNA and complimentary 0.5 mM RNA at 1:1 ratio. Then the
DNA/RNA duplex was annealed by heating up to 80°C for 2 min, and slowly cooling down to
room temperature. Then the duplex mixture was added to 3 mg/mL RNase H at 1:1 ratio in the
presence of 2 mM MgCl2. Crystallization screening was performed with QIAGEN Classics Suite
Kit with 0.2 μL sample and 0.2 μL crystallization buffer by sitting drop vapor diffusion method at
25 °C. The crystals were readily obtained overnight from the mixture #96 of the crystallization
screen [Buffer: 0.1 M MES, pH 6.5; precipitant: 12% (w/v), PEG 20000]. Then the crystallization
was repeated manually with 1 μL sample and 1 μL crystallization buffer equilibrate against 500
μL of 15% (v/v) MPD using hanging drop vapor diffusion method at 25 °C to get more crystals.
The crystal was mounted, shock-frozen in liquid nitrogen with 25% glycerol as cryo-protectant.
The crystals are displayed in Figure 2.8.
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Figure 2.8 RNase H/DNA/RNA complex crystallization.
(A) DNA 2-6; (B) DNA 2-7; (C) DNA 2-8; (D) DNA 2-9.

2.3.3.2 Structure determination of RNase H/DNA/RNA complex
The diffraction data of RNase H/DNA/RNA complex crystal was collected at beamline
8.2.1 and 8.2.2 of the ALS (Advanced Light Source) at the Lawrence Berkeley National
Laboratory. Several crystals were screened to find the crystal with the best diffraction quality. The
diffraction data was collected at 1 Å wavelength for 1 second per frame with 1°oscillation angle.
The best resolution for all 4 different DNA template was about 1.7 - 1.8 Å. The data were
integrated and scaled by HKL2000.
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Table 2.4 Data collection and refinement statistics of RNase H/DNA/RNA complex
Complex structure
Wavelength (Å)
Resolution range
(Å)
Space group
Unit-cell a, b, c (Å)
α, β, γ (°)
Unique reflections
Completeness (%)
Rmerge (%)
I/σ(I)
R value (%)
Rfree (%)
Average B value
(Å2)
R.m.s.d. bond
length (Å)
R.m.s.d. bond
angle (°)

RNase H/ RNA/
DNA 2-6

RNase H/ RNA/
DNA 2-7

RNase H/ RNA/
DNA 2-8

RNase H/ RNA/
DNA 2-9

50.0-1.80
(1.79-1.73)

50.0-1.70
(1.76-1.70)

1
50.0-1.70
(1.76-1.70)

50.0-1.80
(1.86-1.80)
C2

80.2, 37.6, 62.1
90, 96.0, 90
18866 (1081)
92.1 (53.7)
7.7 (23.5)
21 (3.5)
18.9
23.4

81.2, 37.7, 62.2
90, 96.4, 90
17472 (1744)
100 (100)
6.4 (40.8)
29 (3.2)
18.9
21.8

80.9, 37.6, 62.2
90, 96.1, 90
19601 (1917)
99.8 (99.5)
8.9 (22.5)
54 (6.7)
19.2
23.4

81.0, 37.8, 62.0
90, 96.2, 90
20662 (2028)
100 (100)
5.9 (41.4)
31 (3.2)
17.8
22.1

15.6

24.4

27.8

22.1

0.019

0.020

0.021

0.021

1.85

1.98

2.04

2.13

The structure of RNase H/DNA/RNA complex was solved by molecular replacement using
Phaser in CCP4. The corresponding native structure obtained by Dr. Wei Yang’s lab (PDB entry
2g8u; 2.70 Å resolution) with the same sequences was used as model67. The resulting model was
refined using REFMAC in CCP4 and Coot. After several cycles of refinement, water molecules
were added either automatically or manually using Coot. Data collection and structure refinement
statistics are given in Table 2.5. Structure factor and final coordinate have been deposited in the
Protein Data Bank (PDB ID: 5WJR, 5USA, 5USE, and 5USG).
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2.3.3.3 Structure study of selenium atom impact on RNase H active center
As shown in Figure 2.9A, the overall structure and binding site of RNase H/DNA/RNA
complexes are all the same despite modification number and location. In this case, RNase H is
binding to the gap of RNA where the red scissors are in Figure 2.9B. And all four structures are
superimposed very well.

Figure 2.9 Overall structure and binding site of RNase H/DNA/RNA complexes.
(A) Overall structure of RNase H/DNA/RNA complexes. Complex with DNA 2-6 is green, DNA
2-7 is yellow, DNA 2-8 is cyan, DNA 2-9 is red.
(B) Binding site of RNase H/DNA/RNA complexes.

We used RNase H complex with native RNA and DNA 2-9, which has most selenium
modifications, as an example to illustrate why Se-modifications will keep the overall structure in
Figure 2.10. We can find that the RNase H enzyme is binding to the minor groove of DNA/RNA
duplex while selenium modifications are in the major groove because it is modified on 5 position
of thymidine. We believe this is the reason why the RNase H complexes display consistency on
the structure and RNase H enzyme keeps working with modified DNA templates.
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Figure 2.10 RNase H complex structure with native RNA and DNA 2-9
DNA strand is displayed in purple and RNA strand is displayed in cyan.
Yellow spheres represent selenium atoms and red spheres represent magnesium ion.

However, as we investigate the active center of RNase H, we can find some interesting
results. Figure 2.11 display the structure of base pair at the active site of RNase H for all 4
complexes. Because there is no phosphate group at the active center, we consider the distance
between the magnesium ion and 3’-O on the sugar moiety of adenosine onsite as the most
important value that how easy the reaction could happen. We believe the reaction is easier to
happen when this distance is closer. We find if there is a modification on the deoxythymidine at
the complementary place of adenosine onsite (DNA 2-7 and 2-9), the distance between magnesium
ion and 3’-O on the sugar pucker of adenosine get closer. And this may be caused by changes on
base pairs. We collected the related distance data and displayed those in Table 2.5.
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Figure 2.11 Active site structure of RNase H/DNA/RNA complex.
(A) DNA 2-6; (B) DNA 2-7; (C) DNA 2-8; (D) DNA 2-9.

Table 2.5 Important Distance between in RNase H/DNA/RNA complex
Distance (A) Between

DNA 2-6

DNA 2-7

DNA 2-8

DNA 2-9

Mg

O3’/A6

2.56

2.39

2.49

2.37

N3/T2

N1/A6

2.81

2.76

2.80

2.76

O4/T2

N6/A6

2.91

3.04

2.95

3.02

It seems that when there is a 5-Se-T on-site modification, the distance between N3 on dT
and N1 on A get slightly closer, while the hydrogen bond between O4 on dT and N6 on A get
longer. We think the large electron density of Se make the base pairs a little bit unwinding and
push the Adenosine on RNA a little bit into the active core of RNase H and get closer to magnesium
ion there. So in this way, the on-site modification could enhance RNase H activity. Off-site
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modification may also have some indirect impact, and this is why DNA 2-8 also has a shorter
distance between magnesium ion and 3’-O compare with DNA 2-6.
As we accept this hypothesis, we can try to explain the result for RNase H activity research.
Although we are using the same sequences of DNA and RNA in RNase H activity study and
structure determination, the cleavage site and binding site in the crystal are different. In
crystallization, the RNase H binds to the gap between two RNAs. However, if RNase H binds to
the same place in catalysis, RNA could not be cleaved. Only when RNase H active center binds to
the middle of the sequence and there are phosphodiester bonds existing, the cleavage could happen,
and we can observe RNA is cleaved. By investing our previous published paper, we think the
cleavage site on RNA is between A4 and C5 (displayed in Figure 2.12). In this way, DNA 2-8 and
2-9 have the on-site modification while DNA 2-7 and 2-9 have the off-site modification. As we
talked before, the on-site modification could lead to a significant increase in RNase H activity.
This is constant with the catalysis results that DNA 2-9 has the highest RNase H activity and DNA
2-8 comes later.

Figure 2.12 Cleavage site of RNase H catalysis research.
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2.3.4 Cellular level gene silencing with Se-modified antisense DNA
It has been shown that our selenium modification has great potential as antisense drugs,
due to both nuclease stability and RNase H compatibility. To investigate the gene silencing ability
of this novel modified DNA targeting some specific gene in live cells, we performed the
transfection experiment in HeLa cells using some CH3Se-containing DNAs. To visualize the gene
silencing effect, we initially transfected the cells with the eGFP-containing plasmid. The plasmid
was a generous gift from Professor Jenny Yang’s lab, GSU, and the green fluorescence protein
gene was inserted in the pcDNA 3.1+ vector. The antisense oligonucleotide we chose was 18
nucleotides long and targeted to the position 1496 of the eGFP gene. The sequence of antisense
DNA was indicated in Table 2.6, and the CH3Se modification was labeled on those red T. 100 µM
DNA solutions were prepared in water. The HeLa cells were grown in Dulbecco’ MEF containing
10% heat-inactivated fetal bovine serum, 200 µg/mL glutamine, 100 u/mL penicillin, and 100
µg/mL streptomycin at 37 °C, 5% CO2 in a moist atmosphere.

Table 2.6 Sequence information of 5-SeMe-T DNA for cellular experiments
#
2-10
2-11
2-12
2-13
2-14

DNA Sequence
5’-GAG CTG CAC GCT GCC GTC-3’
5’-GAG CTG CAC GCT GCC GTC-3’
5’-GAG CTG CAC GCT GCC GTC-3’
5’-GAG CTG CAC GCT GCC GTC-3’
5’-GAG CTG CAC GCT GCC GTC-3’
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2.3.4.1 Fluorescence determination results

Figure 2.13 Cell images under fluorescence microscope.
(A) Cell images under white light.
(B) Cell images excited by blue light.
(C) Statistic result of fluorescence intensity for all 5 DNAs by plate reader.
(D) Statistic result of fluorescence intensity for different amount of DNA 2-10 and 2-14 by plate
reader.

Cells were seeded in 6-well plates 24 h prior to transfection at a density of 6 x 105 cells
per well and incubated in 3 mL medium. For the transfection, the medium was exchanged with
fresh medium. The eGFP gene-containing plasmid and antisense oligonucleotides were added
simultaneously to the cells with lipofectamine 2000 reagent assisting and incubated for 24 h. After
24 h incubation, the cells were visualized under Axiovert 200 fluorescence microscope excited by
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blue light. The fluorescent intensity was measured by Plate Reader to have an idea about gene
expression level. The results were demonstrated in Figure 2.13. Without transfecting plasmid, no
eGPF was expressed at all (negative control). While without introduction of antisense
oligonucleotides, the eGFP gene was actively expressed (positive control). When Cells were
transfected with both eGFP plasmid and antisense DNAs, the gene expression was significantly
suppressed. And Se-modified antisense DNA made the GFP expression even lower than with
native antisense DNA.

2.3.4.2 Western blotting results
We performed Western Blot experiment to systematically quantify the different
oligonucleotides’ gene silencing activity. After gene expression, HeLa cells were washed three
times with phosphate saline buffer (PBS) and then scraped into 0.1 mL of RIPA lysis buffer
containing the protease inhibitor. After incubation for 10 min on ice, the lysate was transferred to
new tubes, followed by centrifuging at 14,000 g for 15 min at 4°C. After analyzing lysates by SDSPAGE gel, the analysis verified the downregulation of EGFP expression in cells treated with our
antisense DNAs. Moreover, our Se-oligonucleotide has about 20% more gene silencing activity
than the native one. Finally, the relative eGFP expression was calculated as the ratio of the
fluorescence intensity on the control of beta-actin expression. Our quantitative result proved that
DNA 4 and 5 with CH3Se-modifications, silenced the eGFP gene expression more effectively. The
gel image and quantitative result are displayed in Figure 2.14.
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Figure 2.14 Western blotting results.
(A) Gel image for Western blotting.
(B) Quantitative result for Western blotting.

2.4

Conclusion
The derivatization of DNA with selenium can give us a new strategy in the antisense drug

application. The 5-Se-T modification on oligonucleotides provided better resistance to blood
serum. A reasonable hypothesis is that the selenium atoms at 5-position has steric hindrance with
some enzyme residue so that the protein structure slightly shifts and cleavage is inhibited.
Moreover, even though the methyl selenyl group has an impact on nuclease catalysis, it maintains
the RNase H activity when the modified DNA binds to complementary RNA because it does not
cause significant structure changes. And for our case, the modified DNA even lead to higher initial
catalysis rate of RNase H. We think this is because introducing selenium atom to on-site position
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lead to base pair unwinding and the complementary RNA strand is pushed a little bit into the
RNase H activity center. This generates an important pathway for antisense oligonucleotide
working. The gene silencing experiments in HeLa cells also demonstrated that our novel modified
antisense DNA has a brilliant prospective. We anticipate the nucleobase derivatization with
selenium element can provide novel efficient chemical modification strategy in gene therapy
design drug market.

51

3
3.1

SE-ANTISENSE DNA X-RAY FLUORESCENCE IMAGING

Introduction
Massager RNA (mRNA) is the center of the central dogma. It is the bridge between genetic

DNA and functional protein. Translation is the process that ribosomes synthesize protein based on
the information in mRNA. It is very important to understand where and how this process happens.
Most scientists detect this process through newly generated fluorescence protein labeling68.
However, during the translation process, we may not be able to visualize the protein before it is
well folded and modified. When start visualizing the functional protein, it is already translated and
well folded, however, it may not keep the same location where it was synthesized. If we can detect
mRNA and protein at the same time, then we could judge that the place where the signal of mRNA
and protein overlapped is the location that translation is taking place. In this way, not only to
determine the protein but to visualize the localization and transportation of mRNA is very
important to.
Currently, most scientists are using fluorescent labeling for intracellular nucleic acids and
oligonucleotides detection69-72. As a mains research method developed for decades, fluorescent
labeling has many advantages. Since many of the fluorescent molecules with different excitation
and emission wavelengths are developed73, it is possible for us to detect several different targets
with different labeling at the same time. Real-time intracellular monitoring inside living cells is
also accomplished with fluorescent labeling74-75. However, there are still some problems for
nucleic acid detecting with fluorescent labeling. First of all, fluorescent labels are usually some
small molecules attached to 5’ or 3’ of the nucleic acid73. These fluorescent molecules usually
have aromatic rings, which may affect in base stacking and change the structure of nucleic acid.
In this way, they may cause the off-target problem during the experiment. Quenching is another
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possible problem, which will cause low intensity in long-term experiment76. In addition, there
may be also some other molecules that could generate fluorescence on the same excitation
wavelength and cause high background77.
Compared with normal fluorescence detection with small molecule labeling, micro-X-ray
fluorescence (microXRF) detection with specific element could be more specific with higher
intensity and lower background78-79. In this way, microXRF could be a better method for
intracellular large biomolecule detection. Some metal ions have been used as the biosensor to
detect intracellular biological processes involved different enzymes80-85. However, there is no
effective sensor for nucleic acid so far. We developed Se-modified nucleic acids (SeNAs) for
microXRF. SeNAs are single atom modification on nucleic acids. In our previous work SeNAs
show the ability to remain the same structure and properties as native in many cases24-25. And most
of the SeNAs are stable under normal experimental condition. Moreover, the intracellular Se
concentration is very low86, so there could be almost no background for microXRF. All above
conclude that SeNA could be an ideal method for intracellular specific nucleic acid study.
In this way, we designed Se-modified antisense DNA with 5-Se-thymidine and the
sequence targets to green fluorescence protein (GFP) mRNA. When we transfect this antisense
DNA into the cell, it will bond to GFP mRNA (Figure 3.1). We can use microXRF to get the
selenium signal which indicates where mRNA is. Meanwhile, we can also detect new generated
GFP by fluorescence microscope at the same time. After comparing these two signals, we could
tell where translation is taking place.
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Figure 3.1 Processing of the experiment.
After transcription, mRNA come out from nucleus to cytoplasm. Protein is synthesized on
ribosome which binds to mRNA. This processing can be blocked by antisense DNA that has Se
on it in our design.

3.2

Material and Methods
HeLa cell culture on microchips: Check cells in flask under microscope to confirm that

the cells are 80% - 100% confluent. Use the aspirator, empty liquid media covering cells. Use PBS
(5 mL, Thermofisher) to wash the cells for two times. Add trypsin (1 mL, Thermofisher) to flask
and keep in incubator at 37 °C for about 3 min. Check cells in flask under microscope to confirm
that the cells are detached. Add DMEM media (5 mL, Thermofisher) to the cells and then transfer
to a 15 mL tube. Centrifuge cells for 4 min at 1,000 rpm. Remove the supernatant. Cell pellet
should remain at base of tube. Resuspend cells in about DMEM media (10 mL, Thermofisher).
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Place 4-5 microchips in each well of a 6-well plate. Place the resuspended cells in 6-well plates
with microchips.
HeLa cell transfection with microchips: Check cells in flask under microscope to
confirm that the cells are 70% - 90% confluent. Dilute eGFP plasmid (2 μL, 100 ng/μL) and
antisense DNA (0.5 μL, 10 μM) in Opti-MEM medium (200 μL, Thermofisher). Dilute
Lipofectamine Reagent (0.6 μL, Thermofisher) in Opti-MEM medium (200 μL, Thermofisher).
Add diluted DNA to diluted Lipofectamine 2000 reagent and then incubate for 5 min at room
temperature. Add DNA-lipid complex to cells. Let the cells continue growing for 24 h.
Cell Fixation: After 24 h, remove the medium. Wash cells twice with PBS buffer (200 μL
each, Thermofisher) pre-warmed at 37 °C. Fix cells with 3.7% formaldehyde. Incubate at room
temperature for 10 min. Remove 3.7% formaldehyde. Wash the cells with PBS (200 μL each,
Thermofisher) for 3 times. Wash the cells 3 times with isotonic ammonium acetate (0.1 M, 200
μL each) in sterile distilled water. Air-dried overnight, and then take out the chips from wells, store
and ship.
MicroXRF determination: We used XRF microprobe analysis to examine element
distributions and concentrations in cells on microchips at beamline 2-ID-E of the Advanced Photon
Source. An Si(III) single-bounce monochromator was used to tune the undulator synchrotron Xray beam to 12.9 keV. The beam was focused into a 0.5 μm spot using Fresnel zone plate optics.
For element distribution maps, the sample was rastered through the focal spot with a step of 1-2
μm and dwell time of 4 sec. A full energy-dispersive XRF spectrum was collected at each step
using a Canberra three-element UltraLEGe detector (Canberra Instruments, Meriden, CT).
Elemental maps were created by fitting the spectrum at each scan position with modified Gaussians
using MAPS software (Vogt 2003). Area concentrations for elements were calculated by
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comparing integrated intensities of fluorescence peaks with those from thin film standards (NBS
1832 and 1833; National Bureau of Standards, Gaithersburg, MD).

3.3

Results and Discussion

3.3.1 Selenium aggregation of different DNA sequences
Four different sequences of Se-modified DNA are used in the experiment and the
sequences are displayed in Table 3.1. DNA 3-1 (perfect matched) is antisense DNA exactly target
to GFP mRNA. DNA 3-2 is 4 bases mismatched and DNA 3-3 is 6 bases mismatched. DNA 3-4
(control DNA) is a random sequence that is designed not to target any mRNA in HeLa cells. DNA
3-1, 3-2 and 3-3 have 3 modifications on the sequences while DNA 3-4 have only 2 modifications.
In order to make the selenium amount be the same level in cells, the DNA 3-4 was used to be 1.5fold concentration comparing to the other three sequences. We co-transfected the Se-DNAs with
GFP plasmid to HeLa cells at the same time. The X-ray fluorescence microscope images for zinc
and selenium of cell transfected with perfect matched DNA 3-1, mismatched DNA 3-2 and 3-3, as
well as control DNA 3-4 are shown in Figure 3.2. There is a very low level of natural selenium in
human cells, so the selenium background is close to zero. Selenium signal of perfect matched DNA
is focus and appears as condensed spot. For mismatched DNA, we can also determine the
condensed spot signal. However, the intensity of the signal is only about 50% comparing with the
perfect matched group. And there is no condensed spot at all in those cells transfected with control
DNA.
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Table 3.1 Sequence information of 5-SeMe-T DNA for Imaging experiments
DNA sensor
DNA 3-1 (perfect matched)
DNA 3-2 (4 bp mismatched)
DNA 3-3 (6 bp mismatched)
DNA 3-4 (control DNA)

DNA Sequence
5'-GAG CTG CAC GCT GCC GTC-3'
5'-TAT CTG AAC TCT GCA GTA-3'
5'-TAT CTG AAC TCT GCA GTA-3'
5'-CTC CCA TCC-3'

It is obvious that antisense DNA is going to bind and block GFP mRNA at certain area in
the cells, so selenium aggregated at the certain places and appeared to be condensed spots in those
cells transfected with perfect matched and mismatched Se-modified antisense DNA. What’s more,
the cells transfected with mismatched DNA has weaker Se-aggregation phenomenon and the more
bases mismatched, the weaker Se aggregated. We believe the reason for this is that mismatched
DNA has a weaker ability to bind to the target mRNA. Meanwhile, control DNA do not bind to
GFP mRNA at all, so it would be spread to everywhere inside and outside cells, which means no
‘hot spots’ could be found in the images. In the way, the signal of Se also suggests where the target
mRNA is.
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Figure 3.2 Images of Se-oligonucleotides distribution in cells by X-ray fluorescence
visualization.
(A) DNA 3-1 is perfect matched with mRNA.
(B) DNA 3-2 has 4 base pairs mismatched.
(C) DNA 3-3 has 6 base pairs mismatched.
(D) DNA 3-4 is control sequence.

To compare the aggregation of Se more directly, we measured the strongest intensity of
the signal in each picture and the average is displayed in Figure 3.3. The result agrees with our
previous analysis that perfect matched DNA 3-1 has the highest average intensity, mismatched
DNA 3-2 and 3-3 are weaker, and control sequence DNA 3-4 have the weakest signal and it is
close to zero.
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Figure 3.3 Average strongest intensity of Se for the pictures of each DNA.

3.3.2 Certain mRNA distribution in cells
We obtain even more images of Se and Zn for those cells transfected with DNA 1 and they
are displayed in Figure 3.4. As we known, zinc is normally condensed in cell nucleus because of
zinc figure structures87. We consider zinc signal as the location of the nucleus in the cell. Through
the overlap pictures of zinc and selenium signal in Figure 3.2 and 3.4, we can conclude that Seantisense DNAs are outside the nucleus.
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Figure 3.4 More images of Se and Zn distribution in cells transfected with perfect matched
DNA 3-1 by X-ray fluorescence visualization.

It seems that the distribution of Se-antisense DNA is not even in cells. This indicates that
mRNA of GFP is located at some certain places in the cytoplasm. In most of the cells, the signals
are close to the nucleus. However, there are still some cells with selenium signal keeping away
from nucleus. This may indicate that these cells are in different stages of the cell cycle. And we
could speculate the routes of mRNA transportation in this way.
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3.3.3 Co-location of Selenium and GFP
Figure 3.5 displays co-aggregation image of selenium and GFP in the cell transfected with
perfect matched DNA. GFP signal was obtained by fluorescence detection. It seems that the
aggregation spots of selenium and GFP overlap well in Figure 3.5C, which means Se-modified
antisense DNA is located at the position where GFP was synthesized. As we mentioned the Se
signal suggest the location of GFP mRNA, we think the spots that signal of Se and GFP overlapped
are the place that GFP translation is taking place. In this way, we can confirm our hypothesis that
the condensed spots of selenium signal indicate the places GFP is translating.

Figure 3.5 X-ray fluorescence microscope images of cell transfected with DNA 3-1.
(A) GFP fluorescence image;
(B) Selenium X-ray fluorescence image;
(C) Overlap image of Se (red color) and GFP (Green color);
(D) Overlap image of Zn (yellow color) and GFP (Green color).

3.4

Conclusion
We observed that Se-modified perfect matched antisense DNA aggregated surrounding

nucleus in the cytoplasm when transfected with GFP plasmid together. This phenomenon was not
found in those cells transfected with the Se-modified control sequence. Therefore, the Se-modified
antisense DNA is binding the target mRNA at some certain area in cells. By analyzing many cell
images in the different stage of cell cycle, we found that condensed selenium signal spots are
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always away from zinc signal. As we considering zinc signal as the location of nucleus in the cell,
we think Se-modified antisense DNA blocked mRNA outside the nucleus in the cytoplasm.
Meanwhile, the aggregating spot is also the place where GFP is condensed. This result is consistent
with our hypothesis that the condensed spot of Se suggest the position where translation is taking
place. In this way, we can conclude that translation is taking place at certain position in cells and
we can use Se-modified antisense DNA as a biosensor to detect mRNA during this processing.
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4
4.1

DNA/DNA POLMERASE COMPLEX STRUCTURE STUDY

Introduction
DNA polymerases exist in all organisms and replicate genome. Most research on DNA

polymerases is based on DNA Polymerase I (Pol I) from Escherichia coli88. Pol I has three discrete
domains and each of them has different enzymatic activity: 5’-3’ exonuclease, 3’-5’ proofreading
exonuclease, and polymerase activity89. The large C-terminal fragment, which is known as Klenow
fragment (KF), includes both the 3’-5’ exonuclease and polymerase domains90. The structure of
KF was well determined last century91-92. When Pol I is binding to the DNA double strands, the
conformation of the nucleotide is approximately that found in B-form DNA, having a C3’ endo
sugar pucker92.
Many other DNA polymerases from different families were well studied after Pol I
delineated93. One of the most important family is thermostable DNA polymerase, including
Thermus aquaticus DNA polymerase I (Taq)94 and Bacillus stearothermophilus DNA polymerase
I (Bst)95. Those enzymes are very useful and are already widely used to amplify DNA sequences
in polymerase chain reaction (PCR). The structure of both Taq96-97 and Bst98-99 were well
determined.
The large carboxy-terminal fragment of Bst maintains the polymerase catalytic activity,
which allows direct observation of the products of several rounds of nucleotide incorporation. And
Bst just like other Pol I, when binding to the DNA duplex, the sugar pucker of nucleotide was
found a C3’ endo conformation, which is close to B-form DNA.
A big challenge for protein-nucleic acid complex structure determination is that we can
hardly get good crystals for these complexes. So we designed Se-modified-DNA. We would like
to use well studied Bst as an example and test if our Se-modified DNA could make some changes
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when binding to Bst DNA polymerase and whether our Se-modified DNA could facilitate the
complex crystal growth process. This could be a big discovery that Se-modifications on nucleic
acids could not only facilitate the crystal growth for nucleic acids themselves but also works for
protein-nucleic acid complexes. Meanwhile, if the structure of complexes does not have significant
changes, this could give us a different method to grow the protein-nucleic acid complex crystals
and investigate the structure of complexes. In this way, we may solve the problem of complexes
crystallization and determine many more structures of protein-nucleic acid complexes.

4.2

Material and Method

4.2.1 Bst DNA polymerase expression and purification
Transformation of Bst DNA polymerase plasmid to BL21: Place Bst DNA polymerase
plasmids and competent BL21 cell on ice bath. Add plasmid (1 μL, 200 ng/μL) to the competent
cell and keep on ice bath for 30 min. Keep it at 42 °C water bath for 90 s. Then put it back on ice
bath for 3 min. Add S.O.C medium (200 μL, Invitrogen) and shake at 37 °C 225 rpm for 45 min.
Then pour 100 μL to the LB plate with ampicillin (100 μg/mL). Incubate at 37 °C overnight.
Expression of Bst DNA polymerase: Pick single colony from the LB plate into 30 mL
autoclaved LB broth with ampicillin (100 μg/mL). Shake at 37 °C 225 rpm overnight. Then add
10 mL overnight incubated BL21 to each litter of 2×1 L LB broth with ampicillin (100 μg/mL)
and shake at 37 °C 225 rpm for 3 h. Add IPTG (1 mL, 1 mol /L) to each litter of the broth to induce
the expression of RNase H and continue shaking overnight at 20 °C. Harvest the cell by
centrifuging at 4 °C 5,000 rpm for 30 min. Keep the precipitation at -80 °C. Dissolve the cell in
His-tag column buffer A (20 mM Tris pH 7.4, 1 M NaCl, 10 mM Imidazole, 5% Glycerol).
Sonicate the cells with 60 × 15 s bursts. After each 15 s sonication wait 20 s to let the suspension
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cool down. Centrifuge at 4 °C 10,000 rpm for 30 min. Heat up the supernatant to 60-70 °C for
about 10 min. Centrifuge again at 4 °C 10,000 rpm for 30 min. Keep the supernatant at -80 °C.
Purification by His-tag column: Wash the column by buffer B (20 mM Tris-HCl pH 7.4,
1 M NaCl, 300 mM Imidazole, 5% Glycerol) and followed by buffer A each for 5-column-volume.
Load sample. Wash the column by buffer A until the UV value is flat. Then wash the column by
10% buffer B until the UV value almost go back to the low value. Elute sample by gradient from
buffer A to buffer B (up to 100% in 60 min). Dialyze the protein against 2 L Heparin column
buffer A (20 mM Tris-HCl pH 7.4, 100 mM NaCl, 2.8 mM β- Mercaptoethanol, 5% Glycerol)
overnight. Detect the concentration of sample by UV analysis. Use ULP1 to cleavage His-tag by
the concentration of 5 U/mg.
Purification by Heparin column: Wash the Heparin column by buffer B (20 mM TrisHCl pH 7.4, 100 mM NaCl, 2.8 mM β- Mercaptoethanol, 5% Glycerol) and then buffer A (20 mM
Tris-HCl pH 7.4, 1 M NaCl, 2.8 mM β- Mercaptoethanol, 5% Glycerol), each for 5-columnvolume. Load sample. Wash the column by buffer A until the UV value is flat. Elute sample by
program increased buffer B (up to 100% in 60 min). Dialyze the protein against 2 L storage buffer
(20 mM Tris pH 7.4, 2.8 mM β-mercaptoethanol, 100 mM NaCl, 5% Glycerol) overnight.
Concentrate the sample to 24 mg/mL (0.4 mmol/L) and store the enzyme at -80 °C.
SDS-PAGE: Prepare the gel-loading sample with protein sample (2 μL) in mixture of
water (6 μL) and 5×loading buffer (2 μL, 250 mM Tris-HCl pH 6.8, 10% SDS, 0.02%
bromophenol blue, 5% β-mercaptoethanol, 30% Glycerol). Load samples on 4%-15% SDS gel
(Bio-rad) and start electrophoresis in 1 × Running buffer (3.02 g Tris base, 14.4 g glycine, 1 g
SDS, add water to 1 L and adjust pH to 8.3) at 150 V for 40 min. Take out the gel and put in
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Coomassie Brilliant Blue Staining Solution (Bio-Rad) in microwave for 1 min. Then put in
destaining buffer (10% ethanol and 10% acetic acid in water) and shake at 37 °C for 1 h.

4.2.2 Structure study on DNA/Bst DNA polymerase complex
Crystallization of DNA/Bst DNA polymerase complex: 1 mM self-complementary DNA
were annealed by first heating to 90°C for 1 min, and then allowing it to cool slowly down to 25 °C.
The resulting DNA solution was mixed with the protein (final concentration: 24 mg/mL) at 1:1
molar ratio. Co-crystallization of Se-DNA/RNA hybrid with RNase H was achieved by screening
with the QIAGEN Classics Suite Kit (www.qiagen.com). By using the sitting-drop vapor diffusion
method at 25°C, the crystals were readily obtained from the mixture #67 of the crystallization
screen [Salt: 0.2 M Calcium acetate; Buffer: 0.1 M sodium cacodylate, pH 6.5; precipitant: 18%
(w/v), PEG 8000].
Data collection and structure determination: Crystal diffraction data of the SeDNA/RNA/RNase H complex were collected at beamline 8.2.1 and 8.2.2 in the Advanced Light
Source (ALS). 25% glycerol was used as cryoprotectant while X-ray data were collected under the
liquid nitrogen stream at 100 °K. Crystal of DNA/Bst DNA polymerase complex diffracted X-rays
to 1.80. The data were processed and scaled using HKL2000, and the structures were solved by
molecular replacement using Phasing in CCP4i with Dr. Wei Yang solved structure (PDB# 2g8u)
as model. The resulted model was refined using Refmac5 within CCP4i. The modified DNA was
modeled into the structure using Coot. Metal ions and water molecules were added either
automatically or manually using Coot.
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4.2.3 Circular dichroism (CD)
CD spectra: The DNA solution was prepared by diluting to 4 μM in buffer (100 mM NaCl,
10 mM sodium phosphate pH 7.0, 0.1 mM EDTA) and then annealing by heating up to 90 °C for
2 min and then slowly cool down to room temperature. CD spectra were recorded on a JASCO J1500 spectropolarimeter. Four scans of the spectrum were collected over the wavelength range
200 - 350 nm at a scanning rate of 20 nm/min. The average of multiple scans was used for analysis.
The scan of the buffer alone recorded at room temperature was subtracted from the average scans
for each DNA duplex. Data were collected in units of millidegrees versus wavelength and
normalized to total DNA concentration.

4.3

Results and discussions

4.3.1 Bst DNA polymerase expression and purification
The large fragment of DNA polymerase I from Bacillus stearothermophilus (Klenow
Fragment) was expressed and purified in our lab. Protein expressions were carried out in BL21
(DE3; pLys E. coli; purchased from Invitrogen). Because the target protein is thermostable, we
heated the sample to high temperature as a step to purify it. Under higher temperature, while many
other proteins could be denatured and aggregated to precipitate, Bst DNA polymerase could keep
stable and soluble in buffer solution. In this way, we can get purer protein before loading it to the
affinity column for further purifications.
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Figure 4.1 Bst DNA Polymerase Purification
1: Supernatant; 2: After heating 10 min at 60 °C; 3: 1st time for Ni column; 4: After cleavage; 5:
2nd time for Ni column (flow through); 6: Final sample.

After heating and two columns purification, we got very pure Bst DNA polymerase protein
(Figure 4.1). And it is ready for crystallization and structure studies.

4.3.2 DNA/Bst DNA polymerase complex crystallization
Four DNAs shared with same sequence (5’-CGCGAATTCGCG-3’) but modified on
different positions were used for the comparison of DNA/Bst DNA polymerase complex
crystallization. This sequence is well known as Dickerson dodecamer and is normally B form
conformation, which is good for DNA polymerase binding. The sequence and MALDI-MS
analysis information are shown in Table 4.1.
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Table 4.1 MALDI-TOF MASS analysis of Dickerson dodecamer DNA
#
DNA Sequence
Calc. [M-H+]- Observed
4-1 5’- CGC GAA TTC GCG -3’
3645.4
3645.4
4-2 5’- CGC GAA TTC GCG -3’
3724.4
3723.3
4-3 5’- CGC GAA TTC GCG -3’
3724.4
3725.2
4-4 5’- CGC GAA TTC GCG -3’
3803.3
3802.0

The 0.5 mM DNA was annealed by heating up to 80°C for 2 min, and slowly cooling down
to room temperature. Then the DNA was added to 12 mg/mL Bst DNA polymerase at 1:1 ratio.
Crystallization screening was performed with QIAGEN Classics Suite Kit with 0.2 μL sample and
0.2 μL crystallization buffer by sitting drop vapor diffusion method at 25 °C. The crystals were
readily obtained overnight from the mixture #67 of the crystallization screen [Salt: 0.2 M Calcium
acetate; Buffer: 0.1 M sodium cacodylate, pH 6.5; precipitant: 18% (w/v), PEG 8000]. Then the
crystallization was repeated manually with 1 μL sample and 1 μL crystallization buffer equilibrate
against 500 μL of 15% (v/v) MPD using hanging drop vapor diffusion method at 25 °C to get more
crystals. The crystal was mounted, shock-frozen in liquid nitrogen with 25% glycerol as cryoprotectant. The crystals are displayed in Figure 4.2.
There were no significant differences found between native and Se-modified sequences.
The shape and the speed of crystallization are almost the same.
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Figure 4.2 Dickerson dodecamer DNA/Bst DNA polymerase complex crystallization
(A) DNA 4-1; (B) DNA 4-2; (C) DNA 4-3; (D) DNA 4-4.

4.3.3 DNA/Bst DNA polymerase structure study
4.3.3.1 Dickerson dodecamer DNA/Bst DNA polymerase structure study
The diffraction data of Dickerson dodecamer DNA/Bst DNA polymerase complex crystal
was collected at beamline 8.2.1 and 8.2.2 of the ALS (Advanced Light Source) at the Lawrence
Berkeley National Laboratory. Several crystals were screened to find the crystal with the best
diffraction quality. The diffraction data were collected at 1 Å wavelength for 1 second per frame
with 1°oscillation angle. The best resolution for all 4 different DNA template was about 1.8-2.4
Å. The data were integrated and scaled by HKL2000.
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The structure of Dickerson dodecamer DNA/Bst DNA polymerase complex was solved by
molecular replacement using Phaser in CCP4. The corresponding native structure obtained by our
lab previous work (PDB entry 4dsl; 2.45 Å resolution) with the same protein and different DNA
sequence was used as a model. The resulting model was refined using REFMAC in CCP4 and
Coot. After several cycles of refinement, water molecules were added either automatically or
manually using Coot. Data collection and structure refinement statistics are given in Table 4.2.

Table 4.2 Data collection and refinement statistics of Dickerson dodecamer DNA/Bst DNA
polymerase complex
Complex structure

DNA4-1/Bst

DNA4-2/Bst

Wavelength (Å)
Resolution range (Å)

α, β, γ (°)
Unique reflections
Completeness (%)
Rmerge (%)
I/σ(I)
R value (%)
Rfree (%)
Average B value (Å2)
R.m.s.d. bond length
(Å)
R.m.s.d. bond angle
(°)

DNA4-4/Bst

1
50-1.85
(1.92-1.85)

Space group
Unit-cell a, b, c (Å)

DNA4-3/Bst

86.7, 94.1,
105.0
90, 90, 90
73185(6683)
99.1(91.5)
7.4 (43.1)
32.7 (3.6)
18.72
22.36
22.65

50.0-2.13
50-2.40
(2.21-2.13)
(2.49-2.40)
P212121
87.3, 94.2,
86.8, 94.3,
105.8
105.8
90, 90, 90
90, 90, 90
47767(3919)
34483(3357)
96.2 (80)
99.7 (99.1)
13.8 (48.3)
12.9 (50.7)
18.5 (2.8)
20.9 (5.4)
17.91
20.41
22.43
25.65
30.18
26.99

50-2.18
(2.26-2.18)
86.7, 94.2,
105.8
90, 90, 90
45948(4496)
100 (100)
10.6 (48.7)
29.5 (5.7)
17.53
22.49
33.84

0.0189

0.0185

0.0160

0.0192

1.938

2.027

1.857

2.062

As the structures shown of different angles in Figure 4.3, the overall structure of Dickerson
dodecamer DNA/Bst DNA polymerase complexes are quite similar to each other despite the
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different modifications. All four structures are superimposed very well. We believe in this case,
the Se atom specific modifications do not change the structure of the complex as we found on
many other different structures before.

Figure 4.3 Different angle of overall structure of Dickerson dodecamer DNA/Bst DNA
polymerase complex
Complex with DNA 4-1 is green, DNA 4-2 is yellow, DNA 4-3 is cyan, DNA 4-4 is red.

However, we would like to know why these modified DNA duplex will not change the
structure of Bst complexes. We use Bst complex with DNA 4-4, which has the most selenium
atoms, as an example (Figure 4.4) to display the interaction between Bst DNA polymerase and
DNA duplex. We found that the Bst DNA polymerase is binding to the minor groove of DNA
duplex. However, our modification is on 5 position on thymidine which is in the major groove.
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And we notice that there is no interaction between the yellow sphere which represent selenium
atoms and protein in Figure 4.4. Therefore, this modification will not perturb any interaction with
Bst binding, so this modification will not change the overall structure of Bst complex at all.

Figure 4.4 Structure of Bst complex with DNA 4-4
Yellow spheres represent selenium atoms.

Even though the Se-modifications have no impact on the structure of Bst DNA polymerase,
we would like to compare the DNA duplexes in the structure of Bst complexes. The structures are
displayed in Figure 4.5. Though the terminal base pairs show some slight disorder because of its
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flexibility at that position, the main body parts of DNA duplexes display amazing consistency. The
modifications on DNA duplexes do not only keep the overall structure of Bst DNA polymerase
but also have no significant perturbation on DNA duplexes themselves.

Figure 4.5 The structures of DNA duplexes in Bst complexes with Dickerson dodecamer DNA
(A) DNA 4-1; (B) DNA 4-2; (C) DNA 4-3; (D) DNA 4-4.

Another interesting comparison we could do is to compare the structure of Dickerson
dodecamer DNA when it crystallized by itself (PDB entry 3u2n; 1.25 Å resolution) and the
structure of the same sequence in DNA/Bst DNA polymerase complex (Figure 4.6). Again, we
did not find any significant differences between these two structures. We also enlarge the
nucleotide in both structures (Figure 4.6B and D) and find that both sugar puckers are 2’-endo.
This result indicates that Bst DNA polymerase binding will not change the conformation of
Dickerson dodecamer DNA duplex.
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Figure 4.6 Comparation of the structure of Dickerson dodecamer DNA in Bst complex and
crystallized by itself
(A) Structure of Dickerson dodecamer DNA in DNA/Bst DNA polymerase complex;
(B) Nucleotide conformation in Dickerson dodecamer DNA in Bst complex;
(C) Structure of Dickerson dodecamer DNA crystallized by itself;
(D) Nucleotide conformation in Dickerson dodecamer DNA crystallized by itself.

4.3.3.2 (5’-GTGTACAC-3’)2 DNA/Bst DNA polymerase complex structure study
When Bst DNA polymerase binding to the DNA duplex, the sugar pucker of nucleotide
was found a C3’ endo conformation, which is close to B-form DNA. However, some DNA
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duplexes may prefer A-form conformation by its nature. We would like to know when Bst binding
to this kind of DNA sequences, what conformation would the sugar pucker be and whether it will
make any change if we introduce selenium atom to the A-form preferred DNA.
For this part, four DNAs shared with the same sequence (5’-GTGTACAC-3’) but modified
on different positions were used. This sequence was found A form conformation in crystals. The
sequence and mass information are shown in Table 4.3.

Table 4.3 MALDI-TOF MASS analysis of (5’-GTGTACAC-3’)2 DNA
#
4-5
4-6
4-7
4-8

DNA Sequence
Calc. [M-H+]- Observed
5’- GTGTACAC -3’
2410.6
5’- GTGTACAC -3’
2489.6
2489.5
5’- GTGTACAC -3’
2489.6
2489.6
5’- GTGTACAC -3’
2568.5
2569.5

Same crystallization condition was used for this (5’-GTGTACAC-3’)2 DNA/Bst DNA
polymerase complex crystallization. The diffraction data of (5’-GTGTACAC-3’)2 DNA/Bst DNA
polymerase complex crystal was collected at beamline 5.0.2 of the ALS (Advanced Light Source)
at the Lawrence Berkeley National Laboratory. Several crystals were screened to find the crystal
with the best diffraction quality. The diffraction data was collected at 1 Å wavelength for 1 second
per frame with 0.25°oscillation angle. Data processing and structure refinement are all in the same
way comparing with Dickerson dodecamer DNA/Bst DNA polymerase complex. Data collection
and structure refinement statistics are given in Table 4.4.

76

Table 4.4 Data collection and refinement statistics of (5’-GTGTACAC-3’)2 DNA/Bst DNA
polymerase complex
Complex structure

DNA4-5/Bst

DNA4-6/Bst

Wavelength (Å)
Resolution range (Å)

α, β, γ (°)
Unique reflections
Completeness (%)
Rmerge (%)
I/σ(I)
R value (%)
Rfree (%)
Average B value (Å2)
R.m.s.d. bond length
(Å)
R.m.s.d. bond angle
(°)

DNA4-8/Bst

1
50-2.26
(2.34-2.26)

Space group
Unit-cell a, b, c (Å)

DNA4-7/Bst

87.7, 93.7,
106.1
90, 90, 90
41490(4064)
99.7(99.1)
10.8 (52.9)
27.4 (6.4)
18.31
22.87
34.57

50.0-2.64
50-2.38
(2.73-2.64)
(2.47-2.38)
P212121
87.7, 93.8,
86.9, 93.8,
106.0
106.8
90, 90, 90
90, 90, 90
26585(2627)
35893(3514)
100 (100)
100 (100)
13.2 (55.8)
10.6 (53.0)
21.8 (6.6)
31.4 (9.0)
18.17
18.24
23.91
23.60
39.34
37.30

50-2.32
(2.40-2.32)
87.5, 93.8,
106.0
90, 90, 90
25165(2572)
100 (100)
10.8 (52.3)
27.7 (6.9)
17.87
23.10
32.95

0.0185

0.0153

0.0173

0.0182

1.944

1.863

1.920

2.004
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Figure 4.7 Different angle of overall structure of (5’-GTGTACAC-3’)2 DNA/Bst DNA
polymerase complex
Complex with DNA 4-5 is green, DNA 4-6 is yellow, DNA 4-7 is cyan, DNA 4-8 is red.

The overall structures are shown in different angles in Figure 4.7. Similar to the Dickerson
dodecamer sequences, no significant difference was found since all four structures are
superimposed very well. And we think the reason for this consistency of those structures is the
same, that the modifications are in the major groove while Bst DNA polymerase is binding to the
minor groove of DNA duplexes. We use the Bst complex with most modified DNA 4-8 as an
example to illustrate the relationship between the selenium modifications and DNA/Bst DNA
polymerase binding interactions in Figure 4.8.
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Figure 4.8 Structure of Bst complex with DNA 4-8
Yellow spheres represent selenium atoms.

Again, we would like to compare the (5’-GTGTACAC-3’)2 DNA duplexes in the structure
of Bst complexes. The structures are displayed in Figure 4.9. This time the structures of DNA
duplexes are even more similar to each other as this sequence is shorter than the sequence of
Dickerson dodecamer and have less flexibility. As a conclusion based on this case and Dickerson
dodecamer DNA/Bst complexes, we believe the 5-Se-T modifications will not perturb the structure
of DNA duplexes on Bst DNA polymerase complexes regardless the sequence of the DNA.
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Figure 4.9 The structures of DNA duplexes in Bst complexes with (5’-GTGTACAC-3’)2 DNA
(A) DNA 4-1; (B) DNA 4-2; (C) DNA 4-3; (D) DNA 4-4.

We are also interested in whether the (5’-GTGTACAC-3’)2 DNA duplex structure changes
when binding to Bst DNA polymerase. Therefore, we compare the DNA duplex in the complex
with the structure of the same sequence by itself (PDB entry 1d79; 1.45 Å resolution) in Figure
4.10. It is obvious the structure of DNA duplex is completely different. We enlarged one of the
nucleotides in the structure and found some interesting structure changes. Unlike the (5’GTGTACAC-3’)2 DNA duplex crystalized by itself, the sugar puckers of nucleotides in Bst
complex are 2’-endo instead of 3’-endo, which makes the structure is similar to B-form
conformation. What’s more, we find this conformation change in all the Bst DNA polymerase
complexes with Se modified (5’-GTGTACAC-3’)2 DNA, which indicates that the Semodifications do not even have impacts on the conformation shifting of the nucleic acids in nucleic
acid-protein complex in this case.
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Figure 4.10 Comparation of (5’-GTGTACAC-3’)2 DNA in Bst complex and crystallized by
itself
(A) Structure of (5’-GTGTACAC-3’)2 DNA in DNA/Bst DNA polymerase complex;
(B) Nucleotide conformation in (5’-GTGTACAC-3’)2 DNA in Bst complex;
(C) Structure of (5’-GTGTACAC-3’)2 DNA crystallized by itself;
(D) Nucleotide conformation in (5’-GTGTACAC-3’)2 DNA crystallized by itself.

However, the conformation of DNA duplex in crystals may not be exactly the same as it is
in aqueous. Although we determine the DNA duplex conformation changes for (5’-GTGTACAC3’)2 DNA in DNA/Bst DNA polymerase complex compared with the same sequence DNA
crystallized by itself, it does not mean that Bst changes the conformation of DNA duplex. In this
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way, we carried out CD spectra results to analysis the conformation of DNA duplexes in water
solution. The results are displayed in Figure 4.11.

Figure 4.11 CD spectra for native and Se-modified DNAs
(A) CD spectra for native and Se-modified Dickerson dodecamer DNAs. DNA 4-1 is black, DNA
4-2 is red, DNA 4-3 is purple, and DNA 4-4 is green;
(B) CD spectra for native and Se-modified (5’-GTGTACAC-3’)2 DNAs. DNA 4-5 is black, DNA
4-6 is red, DNA 4-7 is purple, and DNA 4-8 is green;
(C) Overlapped CD spectra for native Dickerson dodecamer and (5’-GTGTACAC-3’)2 DNAs.
DNA 4-1 is black, DNA 4-5 is red.
(D) CD spectra for different conformations of DNA duplex100.

The CD result is very interesting. First of all, the spectra of native DNA and Se-modified
DNA are very similar to each other despite different sequences including Dickerson dodecamer
and (5’-GTGTACAC-3’)2. This result indicates that Se-modifications does not only keep the
structure of DNA duplex in Bst/DNA polymerase complexes in crystals but also keep the
conformation of DNA duplexes by themselves in aqueous. On the other hand, the CD spectra of
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these two different sequences are also much alike each other despite some small differences. When
comparing them with the CD spectra of different DNA duplex conformations in Figure 4.11D100101

, both of the DNA duplexes look like B-form DNA in water solution with peak at about 275 nm

and valley at about 250 nm, despite the fact that the DNA duplexes show different conformations
in crystallization. This result could indicate these two different sequences of DNA duplex both
prefer B-form conformation in aqueous instead of A-form conformation. In this way, Bst may only
trap the B-form conformation DNA duplexes in aqueous and lock their conformation while
packing to crystals instead of changing the conformation of (5’-GTGTACAC-3’)2 duplexes when
binding to them. (5’-GTGTACAC-3’)2 duplexes show A-form conformation when crystallized by
themselves because only A-form DNA pack to form crystals. When DNA duplexes were packing
in crystals, the conformation of DNA is locked. In this way, some of the DNA duplexes in aqueous
will change the conformation from B-form to A-form so that the balance of conformations in water
solution could be kept. This is our explanation that why the conformation of (5’-GTGTACAC-3’)2
DNA duplexes is found A-form when crystallized by itself, while the conformation of the same
sequence is found B-form in the crystal of DNA/Bst DNA polymerase complexes.

4.4

Conclusion
Se-modifications do not perturb the structure of the DNA duplex in Bst DNA polymerase

complex. We co-crystallized Bst DNA polymerase with both B-form preferred Dickerson
dodecamer and A-form preferred (5’-GTGTACAC-3’)2 DNAs with different Se-modifications
and determined the structure of complexes. No significant structure perturbation was found
between native DNA and Se-modified DNA in either Dickerson dodecamer or (5’-GTGTACAC3’)2 DNA when binding to Bst DNA polymerase. On the other hand, when Bst DNA polymerase
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binding to DNA duplex, it trapped the B-form DNA duplexes with sugar pucker 2’-endo
conformation in aqueous and lock the conformation for crystal growth, even if the DNA duplex
itself may pack to crystals in A-form duplexes and lock the 3’-endo conformations.
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APPENDIX: TABLES AND FIGURES
The Classics Suite (Qiagen) Screen Kit Conditions
#

Salt

1

0.01 M Cobalt chloride

2
3

0.2 M Magnesium chloride

Buffer
0.1 M Sodium acetate
pH 4.6
0.1 M tri-Sodium
acetate pH 5.6
0.1 M Tris pH 8.5

4
5
6

0.2 M Calcium chloride

7
8

0.2 M tri-Sodium citrate

9

0.2 M tri-Sodium citrate

10

0.2 M Magnesium chloride

11

0.2 M Ammonium acetate

0.1 M HEPES sodium
salt pH 7.5
0.1 M sodium acetate
pH 4.6
0.1M tri-Sodium
citrate pH 5.6
0.1 M HEPES sodium
salt pH 7.5
0.1 M sodium
cacodylate pH 6.5
0.1 M HEPES sodium
salt pH 7.5
0.1 M Tris-HCl pH
8.5

12
13
14

0.1 M Tris pH 8.5

15

0.02 M Calcium chloride

16

0.2 M Sodium chloride

17

0.2 M Ammonium acetate

18

0.2 M Magnesium acetate

19

0.2 M tri-Sodium citrate

20
21
22
23

0.5 M Ammonium sulfate
0.2 M Ammonium phosphate

24
25

0.1 M Sodium acetate
pH 4.6
0.1 M Sodium acetate
pH 4.6
0.1 M tri-Sodium
acetate pH 5.6
0.1 M Sodium
cacodylate pH 6.5
0.1 M HEPES sodium
salt pH 7.5
0.1 M HEPES pH 7.5
0.1 M Tris pH 8.5
0.1 M HEPES pH 7.5
0.1 M Tris pH 8.5
0.1 M tri-Sodium
citrate pH 5.6

Precipitant
1.0 M 1,6-Hexanediol
2.5 M 1,6-Hexanediol
3.4 M 1,6-Hexanediol
5% (v/v) Isopropanol;
2.0 M Ammonium sulfate
10% (v/v) Isopropanol;
20% (w/v) PEG 4000
20% (v/v) Isopropanol
20% (v/v) Isopropanol;
20% (w/v) PEG 4000
20% (v/v) Isopropanol
30% (v/v) Isopropanol
30% (v/v) Isopropanol
30% (v/v) Isopropanol
10% (v/v) Ethanol;
1.5 M Sodium chloride
20% (v/v) Ethanol
25% (v/v) Ethylene glycol
30% (v/v) MPD
30% (v/v) MPD
30% (v/v) MPD
30% (v/v) MPD
30% (v/v) MPD
30% (v/v) MPD
50% (v/v) MPD
70% (v/v) MPD
25% (v/v) tert-Butanol
35% (v/v) tert-Butanol
0.4 M Ammonium phosphate
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0.1 M tri-Sodium
citrate pH 5.6
0.1M Tris·HCl pH 8.5
0.1 M HEPES pH 7.5
0.1 M Sodium acetate
pH 4.6
0.1M Tris·HCl pH 8.5

26
27
28
29
30
31
32
33

0.1 M Sodium chloride
0.01 M Cobalt chloride

34

0.2 M K/Na tartate

0.1 M HEPES pH 7.5
0.1 M MES pH 6.5
0.1 M tri-Sodium
citrate pH 5.6

35
36

38
0.05 M Cadmium sulfate

40
41
42

0.1 M Sodium phosphate; 0.1 M
Potassium phosphate

43
44

0.1 M HEPES sodium
salt pH 7.5
0.1 M Imidazole pH
6.5
0.1 M HEPES pH 7.5
0.1 M Sodium
cacodylate pH 5.6
0.1 M Sodium acetate
pH 4.6

2.0 M Ammonium sulfate
2.0 M Ammonium sulfate
1.6 M Ammonium sulfate
1.8 M Ammonium sulfate
2.0 M Ammonium sulfate

47

0.8 M K/Na tartate
1.0 M Sodium acetate
1.0 M Sodium acetate
1.4 M Sodium acetate
2.0 M Sodium chloride
2.0 M Sodium chloride

0.1 M HEPES pH 7.5
0.1 M HEPES sodium
salt pH 7.5

4.3 M Sodium chloride

0.1 M HEPES sodium
salt pH 7.5
0.1 M Sodium acetate
pH 4.6

46

48

1.4 M tri-Sodium citrate
1.6 M tri-Sodium citrate pH 6.5
0.8 M Sodium phosphate 0.8 M
Potassium phosphate
2.0 M Sodium formate
4.0 M Sodium formate

49

0.1 M Bicine pH 9.0

50

0.1 M MES pH 6.5

51
0.5 M Sodium chloride

53
54

2.0 M Ammonium sulfate

0.1 M MES pH 6.5

45

52

2.0 M Ammonium phosphate
2.0 M Ammonium formate

1.0 M Imidazole pH 7.0
0.4 M K/Na tartate

37

39

1.0 M Ammonium phosphate

0.5 M Sodium chloride; 0.01 M
Magnesium chloride

2% (v/v) Dioxane;
10% (w/v) PEG 20000
10% (v/v) Dioxane;
1.6 M Ammonium sulfate
35% (v/v) Dioxane

0.1 M tri-Sodium
citrate pH 5.6

2% (v/v) Ethylene imine polymer

0.1 M Tris pH 8.5

12% (v/v) Glycerol;
1.5 M Ammonium sulfate

0.01 M CTAB
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55

0.01 M Ferric chloride

56
57

0.5 M Ammonium sulfate

58

0.01 M Nickel chloride

59
60
61
62

0.1 M tri-Sodium
citrate pH 5.6
0.1 M HEPES pH 7.5
0.1 M tri-Sodium
citrate pH 5.6
0.1 M Tris pH 8.5
0.1 M HEPES sodium
salt pH 7.5
0.1 M Bicine pH 9.0
0.1 M MES pH 6.5
0.1 M Tris·HCl pH
8.5
0.1 M HEPES pH 7.5

63
64
65

0.5 M Lithium sulfate

66

0.2 M Zinc acetate

67

0.2 M Calcium acetate

68

0.2 M Magnesium acetate

69

0.05 M Potassium phosphate

70

0.2 M Ammonium sulfate

71

0.2 M Sodium acetate

72

0.2 M Ammonium sulfate

73
74

0.2 M Calcium chloride

75

0.1 M Cadmium chloride

76

0.2 m Magnesium chloride

77

0.2 M tri-Sodium citrate

78
79

0.1 M Sodium chloride
0.01 M Zinc sulfate

0.1 M Sodium
cacodylate pH 6.5
0.1 M Sodium
cacodylate pH 6.5
0.1 M Sodium
cacodylate pH 6.5

20% (v/v) Jeffamine M-600
1.0 M Lithium sulfate
1.0 M Lithium sulfate
1.5 M Lithium sulfate
2.0 M Magnesium chloride
0.2 M Magnesium formate
1.6 M Magnesium sulfate
8% (w/v) PEG 8000
10% (w/v) PEG 8000
15% (w/v) PEG 8000
18% (w/v) PEG 8000
18% (w/v) PEG 8000
20% (w/v) PEG 8000
20% (w/v) PEG 8000

0.1 M Sodium
cacodylate pH 6.5
0.1 M Sodium
cacodylate pH 6.5
0.1 M HEPES sodium
salt pH 7.5
0.1 M HEPES sodium
salt pH 7.5
0.1 M Sodium acetate
pH 4.6
0.1 M HEPES sodium
salt pH 7.5
0.1 M Tris·HCl pH
8.5
0.1 M Bicine pH 9.0
0.1 M MES pH 6.5

80
81

30% (w/v) PEG 8000
30% (w/v) PEG 8000
30% (w/v) PEG 8000
2% (v/v) PEG 400;
2.0 M Ammonium sulfate
28% (v/v) PEG 400
30% (v/v) PEG 400
30% (v/v) PEG 400
30% (v/v) PEG 400
20% (w/v) PEG 550 MME
25% (w/v) PEG 550 MME
10% (w/v) PEG 1000;
10% (w/v) PEG 8000
30% (w/v) PEG 1500

82

0.01 M Nickel chloride

83

0.2 M Ammonium sulfate

84

10% (v/v) Jeffamine M-600

0.1 M Tris pH 8.5
0.1 M Sodium acetate
pH 4.6
0.1 M Sodium acetate
pH 4.6

20% (w/v) PEG 2000 MME
30% (w/v) PEG 2000 MME
8% (w/v) PEG 4000

93

85

0.2 M Ammonium sulfate

86

0.2 M Ammonium acetate

87

0.2 M Ammonium acetate

88

0.2 M Magnesium chloride

89

0.2 M Lithium sulfate

90

0.2 M Sodium acetate

91
92

0.2 M Ammonium sulfate
0.2 M Ammonium sulfate

93

0.1 M Sodium acetate
pH 4.6
0.1 M Sodium acetate
pH 4.6
0.1 M tri-Sodium
citrate pH 5.6
0.1 M Tris·HCl pH
8.5
0.1 M Tris·HCl pH
8.5
0.1 M Tris·HCl pH
8.5
0.1 M MES pH 6.5
0.1 M HEPES pH 7.5

94
95

0.1 M HEPES pH 7.5

96

0.1 M MES pH 6.5

25% (w/v) PEG 4000
30% (w/v) PEG 4000
30% (w/v) PEG 4000
30% (w/v) PEG 4000
30% (w/v) PEG 4000
30% (w/v) PEG 4000
30% (w/v) PEG 4000
30% (w/v) PEG 5000 MME
10% (w/v) PEG 6000;
5% (v/v) MPD
10% (w/v) PEG 6000;
2.0 M Sodium chloride
20% (w/v) PEG 10000;
8% (v/v) Ethylene glycol
12% (w/v) PEG 20000
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Intens.[a.u.]

Mass Spectrum for Important Sequences
7 3 9 7 .4 7 0

7 4 1 9 .3 6 9

2500
7 3 7 5 .4 2 8
7 4 4 1 .6 3 6

2000

7 4 6 3 .6 8 4

1500

7 3 5 3 .1 4 3

7 4 8 5 .6 1 7

7 5 0 8 .1 2 3

1000

7 5 3 0 .2 9 7

7 5 5 2 .3 9 9
500
7 5 7 4 .1 9 7

7 3 0 7 .1 5 3
7 2 6 2 .3 4 6

7 5 9 6 .1 5 8

7 3 2 8 .0 6 9

7 6 2 3 .6 9 8

7 2 4 3 .6 7 7

7 6 6 2 .2 1 1
7 6 8 8 .2 2 2

7 2 0 3 .3 4 5

0
7200

7250

7300

7350

7400

7450

7500

7550

7600

7650

Intens.[a.u.]

m /z

7 4 3 3 .2 4 2

4000

3000

2000
7 4 7 3 .8 3 1

1000
7 4 9 0 .4 4 8

7 5 1 1 .8 3 4
7 3 9 6 .8 0 2
7 3 1 9 .2 2 2

7 0 4 9 .8 0 9

7 5 2 7 .6 8 0

7 6 2 2 .0 2 5

7 3 7 9 .7 3 8

7 6 6 5 .8 0 5
7 7 6 5 .1 4 9 7 8 2 1 .7 9 5

0
7000

7100

7200

7300

7400

7500

7600

7700

7800

7900

8000
m /z

Intens. [a.u.]
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7150.326

2500

2000

6837.081

7244.296

1500
7057.225
6507.470

1000

7439.920
6742.291
6932.735

7287.797

500
6976.464

6603.636

6218.424

7338.753

7022.645

6685.277

7578.094

5913.719
0
6200

6400

Intens. [a.u.]

6000

6600

6800

7000

7200

7400

7600

7800

m/z

7437.170

200

7458.549

150

7475.574

100
7497.520
7515.373

50

0
7300

7350

7400

7450

7500

7550

7600

7650

7700
m/z

Intens. [a.u.]

96

7438.322
2500

2000

1500

1000

7497.089
500

7577.129
7627.426

7343.062

7718.315

0

Intens.[a.u.]

7100

7200

7300

7400

7500

7600

7700

7800

7900

m/z

1807.295

3000

2500

1808.296

2000

1500

1000

1809.335

500

0
1805

1806

1807

1808

1809

1810

1811

1812
m /z

Intens.[a.u.]
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1886.482

8000

1887.479

6000

1888.478

4000

1884.407
1885.482
1883.424

1889.593

2000

1890.554

0
1880

1882

1884

1886

1888

1890

1892

1894

Intens.[a.u.]

m /z

x10 4

1885.716

0.8

1886.707
0.6
1883.713
1887.739
1882.680

0.4

1884.711

1888.770
0.2
1889.725
1879.763
0.0
1878

1880

1882

1884

1886

1888

1890

1892
m /z

Intens.[a.u.]
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1965.190
2500
1963.188

2000

1964.156

1966.194

1500
1962.187

1967.197

1960.190

1000

1968.198
500
1969.184

0
1958

1960

1962

1964

1966

1968

1970

Intens. [a.u.]

m /z
x104

3645.394

2.0

3646.406

1.5

3644.417

3647.385
1.0

0.5

0.0

3642

3644

3646

3648

3650

3652

3654

m/z

Intens. [a.u.]
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x104

3725.261

1.0

3724.307

3726.307
0.8

0.6

3727.311

3723.279

0.4

3722.251

3728.287

0.2

3720.269

0.0

Intens. [a.u.]

3716

3718

3720

3722

3724

x104
2.0

3726

3728

3730

3732

3734
m/z

3730

3732

3734
m/z

3725.220

3724.188

3726.237
1.5

1.0

3727.227
3723.214

3722.209

0.5

3728.231

3720.211

0.0

3716

3718

3720

3722

3724

3726

3728

Intens. [a.u.]

100
x104

3803.960

1.0

3804.960

3803.002
3801.956
0.8

3805.935

0.6

3806.961

3800.968
0.4

3799.989
3808.004
0.2

3798.969

0.0

Intens. [a.u.]

3796

3798

3800

3802

3804

8000

3806

3808

3810

3812

3814

m/z

2489.539

6000

2490.559

2488.542

4000

2487.551

2491.572

2488.575
2000
2485.550
2486.532

2492.608

0
2482

2484

2486

2488

2490

2492

2494

2496

m/z

Intens. [a.u.]

101

2489.580

6000

2490.598

2488.592

4000
2491.578
2487.602

2488.615
2000
2485.600

2492.634

0

Intens. [a.u.]

2484

2486

2488

2490

2492

2494

m/z

2569.466
1250

2567.470
1000

2570.458
2568.504
750

2571.486
500

2566.497
2565.496
2564.448

250
2572.522

0
2564

2566

2568

2570

2572

2574
m/z

